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Polyketides are a class of natural products with a large structural diversity. They find use 
for example in infection-, cancer- and respiratory disease treatments. New discoveries, 
chemical modification and the engineering of polyketide biosynthetic pathways may lead 
to the identification of novel products with altered, potentially improved properties. 
The structural diversity of polyketides originates from the assembly line-like joining 
of simple building blocks by polyketide synthases (PKS). The introduction of structural 
features is guided by the choice of starter units and the incorporation of various extender 
units, such as malonyl- or alkyl-malonyl-CoAs. Enoyl-CoA carboxylases/reductases 
(ECRs) are the key-enzymes providing alkyl-malonyl-CoAs. ECR catalyzed carboxylation 
of α,β-unsaturated enoyl-CoA thioesters, yields in the production of e.g. (2S)-ethyl-
malonyl-CoA. This work presents a route for the preparative scale chemo-enzymatic 
synthesis of a versatile set of extender units. Combining ECR activity with the concept of 
biocatalytic proof-reading for recycling of unwanted byproducts resulted in the efficient 
production of various polyketide extender units. 
This set of extender units enabled tackling the fundamental question, of how 
site-specific incorporation of different extender units in PKS is conveyed. For that, 
phoslactomycin PKS (Pn PKS) derived tetra-, penta- and hexaketide were produced in 
vitro. Furthermore, challenging the Pn PKS assembly line, that naturally incorporates 
malonyl- and ethylmalonyl-CoA, with seven different extender units, revealed a highly 
promiscuous module. With detailed kinetic analysis of excised domains, it could be shown 
that the transacylation reaction is the driving force determining the incorporation of 
extender units.  
Furthermore, in this work, the Pn PKS associated type II thioesterase PnG could 
be shown to possess an editing function and thereby increase the yield of native and 
non-native phoslactomycin derived polyketides in vitro. This work underlines their 
potential for improving the production yields of polyketides. 
In summary, a detailed study of the phoslactomycin PKS, starting from the 
production of extender units, over the in vitro reconstitution of Pn PKS, to the characteriza-
tion of single domains and an accessory thioesterase, is presented. This dissertation 







Polyketide sind Sekundärmetabolite mit einer großen strukturellen Vielfalt. Sie werden 
beispielsweise als Mittel gegen Infektionen, Krebs oder Atemwegserkrankungen 
eingesetzt. Neuentdeckungen, chemische Modifikationen und Engineering von 
Polyketidbiosynthesewegen kann zu neuen Produkten mit veränderten, potentiell 
besseren Eigenschaften führen.  
Die strukturelle Vielfalt von Polyketiden entsteht durch die schrittweise Kopplung 
von einfachen Bausteinen durch Polyketid-Synthasen (PKS), wobei die Auswahl der 
Bausteine, wie Malonyl- und Ethylmalonyl-CoA zum Einbau von strukturellen Merkmalen 
führt. Die Schlüsselenzyme zur Darstellung von Alkylmalonyl-CoAs sind die Enoyl-CoA 
Carboxylasen/Reduktasen (ECRs). Diese Enzyme katalysieren die Carboxylierung von 
α,β-ungesättigten Enoyl-CoA Estern, was in der Produktion von z.B. (2S)-Ethylmalonyl-
CoA resultiert. In dieser Arbeit wird eine preparative chemo-enzymatische Synthese für 
diverse Bausteine präsentiert. Die ECR Aktivität wurde mit dem Konzept des biokataly-
tischen Korrekturlesens zum Wiederverwerten ungewollter Nebenprodukte kombiniert, 
was die effiziente Produktion einer Auswahl von Polyketid-Bausteinen ermöglicht. 
Mit den so hergestellten Bausteinen, konnte der grundlegenden Frage, wie der 
Einbau verschiedener Bausteine vermittelt wird, nachgegangen werden. In dieser Arbeit 
wurden Tetra-, Penta- und Hexaketide des Phoslactomycin PKS (Pn PKS) in vitro 
produziert. Das Pn PKS System wurde mit sieben verschiedenen Bausteinen konfrontiert, 
was zur Identifikation eines promiskuitiven Moduls führte. Detaillierte kinetische 
Untersuchung einzelner Domänen zeigte, dass die Transacylierungsreaktion der 
entscheidende Faktor ist, der zum Einbau von Bausteinen führt.  
Zusätzlich wurde in dieser Arbeit gezeigt, dass die Pn PKS assoziierte Typ II 
Thioesterase PnG, eine PKS-reinigende Funktion aufweist, die zur höheren Produktion 
von nativen und nicht nativen Pn Polyketiden in vitro führt. Dies unterstreicht das Potential 
dieser Enzyme für die Produktion von biosynthetisch veränderten Polyketiden.  
Zusammenfassend ist diese Dissertation eine detaillierte Untersuchung der 
Phoslactomycin PKS, beginnend bei der Produktion versatiler Bausteine, über die in vitro 
Rekonstruierung der Pn PKS, bis hin zur Charakterisierung der zugehörigen Thioesterase 







History of natural products 
Natural products have been used by humans in traditional medicine for centuries. Some 
of the first written records found in Mesopotamia are dating back to the year 2600 BC and 
are collections of information on plant derived substances. Some of these compounds 
are still used in modern medicine for treatments of coughs, parasitic infections and 
inflammations 1. These extracts, often presented as oils were mixtures of multiple 
compounds. The effort to identify single active compounds started in the early 19th century 
with the purification of morphine, atropine and colchicine. Soon after the first 
commercialization of pure natural products, semi-synthetic drugs like aspirin became 
available 1.  
The applications of natural products in human medicine cover many roles including 
fighting infections, lowering cholesterol levels and treating cancer 2, 3. Besides in human 
medicine, they are also applied in veterinary medicine and agriculture 4. In the past 
decades the number of natural products or natural product-derived drugs has risen to 
roughly 34% of all drugs on the market with an additional 20% of synthetic drugs 
containing natural product pharmacophores. In the field of antibacterials this number even 
reaches 55% 5, underlining their indispensability in modern medicine.  
Natural products are omnipresent, as they are found all over the tree of life in 
bacteria, fungi, plant and animals 4, 6. In the kingdom of bacteria, the family Actinomycetes 
has proven to be a rich source of various compounds. Two thirds of the known antibiotics 
are produced by them, the majority by Streptomycetes 7. Depending on the biosynthetic 
origin, natural products are divided into polyketides, non-ribosomal peptides, terpenes, 
alkaloids and lanthipeptides amongst others. All these compounds are produced by 
secondary metabolism and are thus not required for survival itself, nevertheless they 
provide advantages for the producer in the native environment. The biological function of 
these compounds is diverse but not limited to defense - serving as toxins and antibiotics, 
communication, quorum sensing, virulence and pigmentation 2, 8, 9.  
Polyketides comprising of polyethers, polyenes, polyphenols, macrolides and 
enediynes are one of the major classes of natural products and a significant source of 
new drugs and bioactive small molecules. Some representatives such as erythromycin, 
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doxorubicin, epothilone B, ivermectin and lovastatin, which are used as antibiotic, 
antitumor, anti-parasitic and cholesterol lowering agents are blockbuster drugs with a 
great impact on modern civilization 10.  
  
Biosynthesis of polyketides 
Polyketide synthases (PKS) and fatty acid synthases (FAS) share a common evolutionary 
history and thus show similar biosynthetic characteristics in precursor usage, domain 
organization and catalytic mechanism 3, 11, 12. The products formed by both enzyme 
classes are assembled in an assembly line fashion by the repetitive action of catalytic 
units (termed domains). The acyltransferase (AT) selects the substrate and transfers it 
from CoA to the thiol group of the phosphopantetheine arm of the cognate acyl-carrier 
protein (ACP). This prosthetic group serves as a flexible arm that shuttles the growing 
polyketide chain between domains. The β-ketoacylsynthase (KS) catalyzes a C-C bond 
formation between the acyl-unit bound to a cysteine thiol and the extender unit bound to 
the ACP. This condensation results in a two-carbon head-to-tail elongation of the growing 
polyketide. By the irreversible elimination of CO2 a reactive enolate anion is formed, which 
serves as a nucleophile to extend the polyketide. This reaction is termed decarboxylative 
Claisen condensation.  Following chain elongation, the β-keto group can be successively 
reduced by a ketoreductase (KR), dehydratase (DH) and enoyl reductase (ER), finally 
resulting in a saturated acyl-chain. In some cases, a methyltransferase (MT) is embedded 
in the assembly line and can add an α-methyl branch 2, 13. Multiple repetitions of this cycle 
are performed until the full length of the product is reached, which is then typically 
released by a thioesterase (TE) (Figure 1).  
The evolutionary separation of FAS and PKS represents a branching point 
between primary and secondary metabolism 2. Besides the fundamental similarities 
between these two protein classes, there are also characteristic differences that lead to 
the immense structural diversity of polyketides compared to fatty acids. PKS use a 
broader range of substrates, going beyond acetyl- and malonyl-CoA commonly used by 
FAS. Furthermore, they use different mechanisms to control product chain length and in 
contrast to FAS, the reductive steps are optional giving rise to multiple functional groups.  
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Assembly of the polyketide backbone thus sets the basis of structural diversity by 
variable chain lengths, incorporation of α-substituted extender units, extent of β-reduction 
(resulting in β-keto, β-hydroxy, α,β-olefinic or β-CH2 methylene groups) and installation 
of varying stereochemistry of the α-side chains, β-groups and double bonds resulting in 
an apparently infinite number of combinations. After biosynthesis of the carbon backbone, 
polyketides undergo extensive decoration such as oxidation, glycosylation, amination and 




Figure 1: Basic steps in polyketide assembly with the involved domains. Ketoacylsynthase (KS), 
acyltransferase (AT), acyl carrier protein (ACP), ketoreductase (KR), dehydratase (DH), enoylreductase 
(ER) and thioesterase (TE).  
 
Polyketide biosynthetic enzymes are divided into three classes. Type I PKS are 
exceptionally large, multifunctional, multi-domain enzymes with covalently linked domains 
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that are organized in modules (Figure 2). They are categorized into iterative and 
non-iterative PKS. In iterative modular PKS each module conducts multiple elongation 
and reduction reactions. In non-iterative modular PKS each module is responsible for a 
single elongation and a set of optional reduction steps. The assembly of their products 
follow the co-linearity rule, where the polyketide backbone can be predicted upon domain 
specificities and modules present 2, 3, 14-16.  
 
 
Figure 2: Phoslactomycin PKS from Streptomyces platensis as an example for a modular type I PKS 
system. The domains are organized in modules, that assemble to form the megasynthase complex. 
AT=Acyltransferase, ACP=Acyl-carrier protein, KS=Ketosynthase, DH=Dehydratase, KR=Ketoreductase. 
1=cyclohexanecarboxyl-CoA, 2=malonyl-CoA, 3=(2S)-ethylmalonyl-CoA. The polyketide is handed on from 
the first module PnA downstream to the last module PnF. After reaching full length the the octaketide (4) is 
released by lactonization catalyzed by the terminal TE (Thioesterase).   
 
A special type of modular PKS are the trans-AT PKS, where one or multiple 
free-standing trans-acting ATs load the extender unit onto their ACP partner. This type of 
PKS generally does not follow the cis-AT PKS co-linearity rule. However, significant 
progress based on domain sequences has been made to predict the potential trans-AT 
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polyketide structure 17. Type II PKS are discrete mono-functional enzymes that assemble 
into dissociable complexes and iteratively elongate the polyketide 18. Type III PKS, also 
known as chalcone synthase type proteins, are multifunctional enzymes selecting the 
starter unit, assembling the product and cyclizing it, in an ACP-independent manner 19.  
 
The structure of polyketide synthases 
Until now, no crystal structure of a complete PKS module could be produced. 
Nevertheless, high resolution structures of multiple excised domains and some 
di-domains have been successfully solved. Remarkably, a cryogenic electron microscopy 
(cryo-EM) structure of the full pikromycin module (PikAIII) has been reported 20-26. While 
this presents a great achievement towards final structure elucidation of modular PKS, the 
cryo-EM structure is debated and a precise picture of PKS module structure cannot been 
drawn, due to inconsistencies between the cryo-EM and crystal structures 27, 28. 
A common feature of recent models is that the condensing domains (KS-AT) and 
the modifying domains (DH-ER-KR-ACP) are separated into two distinct regions as 
observed in metazoan FAS 29. PKS are homodimeric enzymes with the KS, DH and TE 
domains being responsible for the dimerization. Additional short sequence motifs 
responsible for coiled-coil interactions, located at the N-terminus of the KS, KR and the 
C-terminus of the ACP have been identified to stabilize the homodimerization of PKS 
modules and the interaction with the downstream module 30, 31. ER domains are members 
of the MDR superfamily, which predominantly exist as dimers or tetramers. Yet, data on 
the oligomeric state of PKS ER domains support the dimeric as well as a monomeric state 
22, 23. Between non-iterative and iterative modular PKS, the oligomeric state of the ER 
domain could be an important structural difference. In the crystal structure of the iterative 
mycocerosic acid synthase (MAS)-like PKS, which is closely related to modular PKS, the 
ER is found to be dimeric 32. This structural feature is supported by the longer ER-KR 
linker sequences of iterative PKS compared to the linker sequences in modular PKS, 
which enables dimerization 27.  
It was found that the DH dimer behaves as a rigid body, while the following ER 
domain exhibits slight flexibility, followed by the KR as the catalytic active domain with the 
highest flexibility 32. During biosynthesis, the substrate is tethered to the ACP and shuffled 
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between the various domains. With the cryo-EM analysis of PikAIII a striking ACP 
movement depending on the phosphopantetheine-arm linked acyl-residue was 
observed 33. A high-resolution structure of a PKS is necessary to fully understand the 
mechanism behind polyketide biosynthesis, domain interaction and ACP movement. This 
will result in the efficient guiding of the engineering of these highly complex systems.  
 
Origin of the structural backbone diversity 
An important mechanism accounting for the structural diversity of polyketides is the use 
of starter units other than acetyl-CoA, such as cyclohexanecarboxyl-CoA in 
phoslactomycin, p-aminobenzoic acid in candicidin,  or isovaleryl-CoA in avermectin 34-36.  
Following starter unit selection, most PKS use malonyl-CoA as an extender unit. 
In rarer cases, α-substituted extender units are used, leading to the incorporation of 
alkyl-residues at the at the α-carbon of polyketides. This is seen for example in the 
antibiotic erythromycin, which originates from the exclusive incorporation of 
methylmalonyl-CoA provided by the propionyl-CoA carboxylase 37. With the growing 
number of polyketides characterized, more atypical α-substituted extender units were 
identified, such as ethylmalonyl-, benzylmalonyl-, hexylmalonyl- or allylmalonyl-CoA 38-41.  
Most of these rare extender units are provided by enoyl-CoA 
carboxylase/reductases (ECRs). These enzymes are members of the medium-chain 
reductase/dehydrogenase (MDR) protein superfamily and catalyze the formation of a C-C 
bond between an α,β-unsaturated enoyl-CoA thioester and the electrophile CO2.  The 
reductive carboxylation is done in a stereospecific manner, resulting in (2S)-alkyl-malonyl-
CoA derivatives suited for polyketide biosynthesis 42, 43. ECRs are distinguished in two 
subfamilies, ECR-I from primary metabolism and ECR-II from secondary metabolism. 
While both can produce ethylmalonyl-CoA, PKS mainly draw their extender units from 
ECR-II activity 44. These carboxylases show the side reaction of simply reducing the 
unsaturated CoA thioester without carboxylation, as a remnant of their evolutionary origin, 
resulting in saturated alkyl-chains (Figure 3). This is vividly demonstrated by the ECR 




Figure 3: Reaction scheme of enoyl-CoA carboxylase/reductases (ECRs). The ECR can carboxylate the 
α,β-unsaturated substrate 1 NADPH dependently, resulting in 2, an α-substituted malonyl-CoA derivative. 
In a side reaction or in absence of CO2 the substrate can be reduced to 3, an alkyl-CoA. R = alkyl residues.  
 
The genes encoding for secondary ECRs are often located within or in proximity of the 
biosynthetic gene cluster of the respective PKS that incorporates atypical extender 
units 44. After the characterization of their carboxylation activity and role in 
ethylmalonyl-CoA production, the use of ECRs in synthesizing atypical extender units 
was soon demonstrated. Not only malonyl-CoA derivatives with linear or branched 
alkyl-substitutions could be synthesized but also substitutions bearing allyl-groups. These 
developments led to the production of unprecedented polyketide structures 41, 43, 45-48.  
 
Acyltransferases select starter and extender units 
The AT domains are responsible for the selection of specific starter and extender units 
and consequently also for the α-substitutions of the polyketide. Their role in polyketide 
biosynthesis made them the major target of engineering efforts with the aim of creating 










specificity for their substrate, which is conveyed by specificity motifs. A common motif lies 
downstream of the GXSXG sequence motif containing the active site serine. In malonyl-
CoA specific AT domains a phenylalanine is placed in proximity to that motif, which is 
replaced commonly with a glycine or serine in methyl and ethylmalonyl-CoA 
transacylating ATs 49-51. Another intensively studied motif is the highly conserved HAFH 
motif in the binding pocket of malonyl-CoA transacylating AT domains. Methylmalonyl-
CoA specific domains mostly present a YASH motif. In AT domains transacylating 
ethylmalonyl-CoA and longer acyl-residues this motif is less well conserved. In the case 
of ethylmalonyl-CoA ATs it generally presents the sequence XAGH, with X mainly being 
F, T, V or H 52. Attempts have been made to exchange complete sequence motifs or 
swapping entire AT domains exhibiting different substrate profiles, resulting in the 
production of chimeric PKS 53-55. These constructs often resulted in insoluble protein, very 
low activities and increased promiscuity rather than specificity changes. A less invasive 
strategy is the exchange of individual specificity conferring amino acids by site-directed 
mutagenesis, which as well often resulted in promiscuous AT domains 52, 56-58. The 
difficulties in achieving full inversion of specificity highlight an incomplete understanding 
of which amino acid residues are involved in substrate selection. Recently a series of 
previously unidentified amino acids participating in substrate selection were 
characterized, where even single mutations led to a shifted selectivity. Guided by the new 
findings, exchanges of larger structural motifs than anticipated before, led to almost 
complete shifts towards larger substrates in the pikromycin system 59.   
Reports on naturally promiscuous AT domains are increasing, providing platforms 
for the diversification of polyketides with little to no engineering 60, 61. The AT5 of monensin 
PKS selects naturally for methyl- and ethylmalonyl-CoA. Nevertheless, it was shown that 
this domain also accepts allyl-, propargyl- and butylmalonyl-CoA, resulting in novel 
monensin derivatives without the need for engineering 62, 63.  The erythromycin modular 
type I PKS DEBS, generates the macrolide 6-deoxyerythronolide B (6-dEB) from 
propionyl- and methylmalonyl-CoA. This PKS is the archetypal model system for 
investigating PKS mechanisms, specificity and engineering. Heterologous production of 
6-dEB has been achieved in a metabolically engineered E.coli strain BAP1 and later the 
DEBS system was reconstituted in vitro yielding the full macrolide, as well as truncated 
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lactone versions 64-67. Initial assumptions that the DEBS AT domains exclusively accept 
methylmalonyl-CoA as substrate were soon revealed to not hold true, as experiments 
showed an intrinsic promiscuity leading to the incorporation of butylmalonyl-, 
propargylmalonyl- or azidoethylmalonyl-CoA68, 69. The same was shown for the 
pikromycin PKS that synthesizes a structurally highly similar polyketide, in which 
incorporation of, for instance ethyl- and propargylmalonyl-CoA was observed 60, 70. The 
inherent promiscuity of AT domains complicates the study of specificity-conferring amino 
acids and hinders the targeted incorporation of atypical extender units. Yet, at the same 
time such AT domains offer the opportunity to be exploited as platforms for polyketide 
diversification.  
 
Thioesterases in polyketide biosynthesis 
Once the polyketide chain reaches full length, it is released from its thioester tether of the 
ACP. Typically, in modular PKS the last biosynthetic module contains a covalently bound, 
terminal type I thioesterase domain (TEI) which catalyzes the release of the polyketide by 
hydrolysis or intramolecular macrocyclization. Nonetheless, other release mechanisms 
are also known 71. TEs are members of the α,β hydrolase superfamily that contain a 
catalytic Ser-His-Asp triad with the active site serine serving as a nucleophile 72. 
Polyketide TEIs are dimeric and contain a hydrophobic substrate channel which stretches 
through the entire domain to accommodate the polyketide. Release is catalyzed by the 
transfer of the polyketide chain to the active site serine, forming an acyl-O-TE 
intermediate. This intermediate can either be captured by an external nucleophile like 
water, or by an internal nucleophile like a hydroxyl- or amine-group leading to a linear or 
cyclic product, respectively. For cyclization resulting in lactones and lactams the 
acyl-O-TE intermediate must be protected from solvent nucleophiles, while the polyketide 
chain is precisely positioned in the TE to allow regiospecific capture of the carbonyl by an 
internal nucleophile 73, 74. In natural systems the TEI is presented the final, native product. 
This is usually only a single compound; substrate selection is thus not required. In the 
case of pikromyin, the terminal TE is releasing the heptaketide as well as a hexaketide 75. 
This indicates a relaxed substrate specificity of TEIs. Studies on the terminal TE from 
DEBS, TEDEBS, and fusions for the production of truncated polyketide derivatives showed 
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only a modest substrate preference of this TE, favoring the natural (2R, 3S) configuration 
of the 2-methyl-3-hydroxy substituents in the presence of a distal hydroxyl-group 76-78.  
In addition to the terminal TE, many polyketide biosynthetic clusters contain an 
external thioesterase, known as type II TE (TEII). The result of knocking out these proteins 
can reach from no effect, to a complete loss of product formation 79-82. TEIIs generally 
have a beneficial effect on increasing the production yield, which can be exploited by 
co-expression in heterologous systems 83, 84. Strong overexpression on the other hand is 
observed to reduce product formation 82, 85. The main role of TEIIs is suggested to be the 
removal of modifications blocking the reactive thiol of the 4’-phosphohantetheinyl arm of 
ACPs, leading to a stalling of the biosynthesis. Besides this clearing activity, also other 
functions have been observed 80, 81, 86-90. Two potential origins of structures blocking the 
assembly line are discussed in literature. The first is decarboxylation of extender units 
tethered to the ACP by the KS domain, without following elongation 91-93. The second is 
the conversion of the apo-ACP into the holo-ACP by phosphopantetheinyl transferases 
that utilize acyl-CoA thioesters instead of free CoA-SH. This leads to the loading of the 
acyl residue onto the ACP and consequently to a blockage of the assembly line.  
Furthermore, two models for the action of TEII have been proposed. In the high 
specificity model, the TEII efficiently removes exclusively aberrant acyl residues. In the 
low specificity model, the TEII inefficiently removes correct and aberrant acyl residues 91, 
94. The correct residues, including growing polyketide chains are protected from 
hydrolysis by efficient processing through the PKS, aberrant residues cannot be 
processed, or only slowly, and are exposed on the surface for an increased period of 
time, enabling the TEII to attack and hydrolyze the residues.  
 
Aim of this study 
After recognizing the native incorporation of various α-substituted extender units into 
polyketides, investigations of AT domains aimed to help understand the biochemistry 
behind substrate selectivity. Inspired by this, the production of novel polyketides mediated 
by the incorporation of non-native extender units was attempted through assembly line 
engineering. A major difficulty that limits thorough AT characterization, is the availability 
of extender units. The commonly used synthetic production route of extender units is the 
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utilization of a promiscuous MatB variant 68, 95, 96. This route however shows many 
disadvantages. Chapter I describes how ECRs can be used for the production of a 
versatile set of α-substituted malonyl-CoA derivatives. The carboxylation efficiency of a 
promiscuous ECR was maximized by coupling the reaction to a biocatalytic proofreading 
mechanism. For this, an oxidase was employed that recycles the reduction side reaction 
products of the ECR back into the α,β unsaturated starting substrates. Furthermore, a 
convenient preparative scale, high purity assuring “one-pot” workflow for the production 
of atypical extender units was established and the incorporation of these extender units 
into polyketides could be demonstrated. With this study, the basis to facilitate the 
exploration of AT domains and PKS promiscuity and engineering is set. 
 
Only a few reliable and well established PKS model systems are available for in vitro 
studies. Two of them are the archetypal modular DEBS system and the PikA PKS. Both 
of these systems show intrinsic promiscuity of multiple AT domains 60, 68, 70, 97, which 
complicates the study of selectivity conferring properties. To fundamentally understand 
how extender unit selectivity is achieved, more diverse systems are required. Chapter II 
focuses on the modular type I PKS of phoslactomycin (Pn PKS) from Streptomyces 
platensis. This PKS system displays unique features, like the selection for the rare starter 
unit cyclohexanecarboxyl-CoA, the incorporation of five molecules malonyl- and two 
molecules ethylmalonyl-CoA and the generation of two cis-double bonds. These 
properties make Pn PKS an excellent model to study selectivity at different sites in one 
PKS. This chapter describes the successful in vitro reconstitution of the first six modules 
of Pn PKS. Competitive substrate incorporation assays revealed a module with high 
substrate tolerance. Combined with a steady state kinetic assay, established for this work, 
the reaction parameters of excised AT domains could be assessed. With this, the 
mechanism behind substrate selection of this promiscuous AT domain could be 
unraveled. This study provides a PKS model system, complementary to those commonly 
used, and demonstrates the pursue of mechanistic questions in the context of an 




PKS in vitro and in vivo studies often neglect possible effects on the polyketide production 
yields, which could be caused by additional enzymes present in the producer organisms. 
Most information about the function of type II thioesterases, enzymes encoded in the 
majority of polyketide biosynthetic gene clusters, has been gained by in vivo knock out 
experiments. Only a few in vitro experiments have been done combining TEIIs with their 
associated biosynthetic enzymes 85, 98, while the impact of TEIIs on polyketide production 
of modular type I PKS in vitro remains unexplored. In Chapter III, the effects of PnG, the 
TEII from the phoslactomycin PKS, on the previously reconstituted in vitro system are 
presented. Kinetic analysis of PnG with ACP tethered (alkyl)malonyl- and alkyl- residues 
showed a strong preference for alkyl-ACPs, representing assembly line blocking 
modifications. When added to the in vitro Pn PKS system, low amounts of PnG increased 
polyketide production of the assembly line, suggesting substantial blocking thereof. PnG 
could moreover be shown to release polyketides, functionally replacing the terminal 
thioesterase in vitro. Careful evaluation of the data suggests that the origin of the residues 
blocking the assembly line are the miss-loading by phosphopantetheinyl transferases but 
as well as decarboxylation of extender units in situ. Put together, the results support the 
low specificity model of TEIIs and highlight the utility of these enzymes for improving 
natural product biosynthesis in vitro.  
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Summary 
The incorporation of different extender units generates structural diversity in polyketides. 
There is significant interest in engineering substrate specificity of polyketide synthases 
(PKSs) to change their chemical structure. Efforts to change extender unit selectivity are 
hindered by the lack of simple screening methods and easily available atypical extender 
units. Here, we present a chemo-biosynthetic strategy that employs biocatalytic 
proofreading and allows access to a large variety of extender units. First, saturated acids 
are chemically coupled to free coenzyme A (CoA). The corresponding acyl-CoAs are then 
converted to alkyl-malonyl-CoAs in a ‘‘one-pot’’ reaction through the combined action of 
an acyl-CoA oxidase and enoyl-CoA carboxylase/reductase. We synthesized six different 
extender units and used them in in vitro competition screens to investigate active site 
residues conferring extender unit selectivity. Our results show the importance of an 
uncharacterized glutamine in extender unit selectivity and open the possibility for 








Polyketides are a large class of structurally diverse natural products that exhibit a myriad 
of biological activities ranging from antibacterial, to antifungal, cholesterol lowering, 
immune system suppressing, and more 1. Although polyketides show a large structural 
and functional variety, they are all assembled from simple acyl- and alkylmalonyl-thioester 
building blocks. The building blocks are combined in successive Claisen-condensation 
reactions catalyzed by large multidomain enzymes, so-called polyketide synthases 
(PKSs). Structural diversity in the final polyketide product is achieved by a variety of 
different mechanisms. One important mechanism to generate structural variety in 
polyketides is the use of different acyl-coenzyme A (CoA) building blocks (“starter units”) 
and their condensation with different alkymalonyl-CoA building blocks (“extender units”) 
during biosynthesis 2. While PKSs have been recognized to accept a variety of different 
acyl-CoA starter units 3 , the extension of the growing polyketide chain was for a long time 
believed to be restricted to malonyl-CoA and methylmalonyl-CoA units. However, the 
growing number of PKSs that are able to incorporate atypical alkylmalonyl-CoA extender 
units, such as ethylmalonyl-, benzylmalonyl-, or octanoylmalonyl-CoA, highlights the 
importance of this principle in the generation of structurally and functionally diverse 
polyketides 2. 
Most of the atypical extender units are provided via the reductive carboxylation of 
unsaturated acyl-CoA precursors by enoyl-CoA carboxylase/reductases 4-6. Genes 
encoding carboxylating enoyl-thioester reductases (ECRs) are often associated with the 
biosynthetic gene cluster of the respective PKS that incorporates the atypical extender 
unit. Recent studies on the biochemistry of the ECRs identified active site residues that 
determine the substrate spectrum of these enzymes 7. According to these studies, ECRs 
can be categorized into two subfamilies; the ECR-1 subfamily that possess a rather 
narrow substrate spectrum, and the ECR-2 subfamily that display a more relaxed 
substrate specificity 6, 7.  
The incorporation of atypical extender units through the targeted reprogramming 
of PKSs has become an important focus in bioengineering to create polyketides that show 
novel properties. Most approaches in this direction focus on the manipulation of the 
acyltransferase (AT) domains that are part of the PKS biosynthetic machinery. ATs are 
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often described as the “gatekeeper” domains that decide which extender units will enter 
the PKS assembly line. In contrast, the downstream domains of the PKSs that perform 
the actual condensation and modification reactions are believed to be rather promiscuous 
towards unnatural α-substituents 8-11. Several different strategies to manipulate the 
specificity of extender unit incorporation have been applied up to date 12-14. Although it 
has become possible to incorporate atypical extender units, this was mainly achieved by 
lowering selectivity of ATs towards their native extender unit, which is very often 
accompanied by strongly reduced overall activities. An improved specificity by improving 
the desired selectivity in combination with reducing the native selectivity by a point 
mutation has to our knowledge only been achieved in one case 13. This highlights the 
necessity for more comprehensive screening methods to fully understand the 
contributions of ATs and other PKS domains toward extender unit specificity. 
Another difficulty that complicates AT engineering is the limited availability of 
atypical extender unit variants that can be used to screen for altered specificities of ATs. 
Commonly atypical extender units are synthesized in situ via enzymatic coupling of 
malonic acid derivatives and CoA using a promiscuous variant of the malonyl-CoA 
synthetase MatB from Rhizobium trifolii 10, 11, 15. This synthesis route is, however, 
restricted by the limited number of commercially available malonic acid derivatives, which 
otherwise have to be laboriously synthesized via the acylation of Meldrum's acid 16. The 
recent description of promiscuous ECRs has opened up new routes for the 
chemo-enzymatic synthesis of atypical extender units at preparative scale7. However, 
promiscuous ECRs often display a significant side reactivity and simply reduce the 
unsaturated acyl-CoA precursors instead of carboxylation. As an example, AntE, the 
reductive carboxylase in the antimycin biosynthesis pathway, carboxylates only 25% of 
one of its natural substrates cinnamoyl-CoA, while the rest of the substrate is reduced to 
phenylpropionyl-CoA (“dihydrocinnamoyl-CoA”) 17.  
Here we increased the carboxylation yield of promiscuous ECRs by applying the 
principle of biocatalytic proofreading. We successfully coupled promiscuous ECRs with 
an acyl-CoA oxidase that is able to continuously recycle the reduction reaction side 
product, pushing the ECR reaction toward the carboxylation product. Based on this 
principle, we further developed a chemo-biosynthetic route that allows for the convenient 
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preparation of atypical alkylmalonyl-CoA extender units from simple starting materials in 
“one pot” and at high carboxylation yield. We use this route to prepare a set of six different 
alkyl-mlalonyl-CoA extender units at preparative scale and high purity, and demonstrate 
with a recently established in vitro model system of the DEBS PKS 18 that these extender 










Results and Discussion 
Screening of ECRs for the production of atypical polyketide extender units from 
enoyl-CoAs 
To first identify suitable ECRs for the preparative-scale synthesis of alkyl-malonyl-CoA 
ester, we tested six different homologs with respect to their biosynthetic potential. Our 
screen included ECRs that either had been described to show relaxed substrate 
specificity, were part of a cluster described to produce a polyketide with atypical extender 
units, or contained an active site motif indicating promiscuity (Table S1). In addition, we 
tested an ECR variant of C. crescentus (CcrCPAG) that was recently engineered from a 
specific into a promiscuous enzyme through three active site mutations (C146P, I169A, 
and F373G) 7. The six ECRs were tested on five different enoyl-CoA thioesters of varying 
chain length and branching patterns; crotonyl-, hexenoyl-, 5-methylhexenoyl-, octenoyl-, 
and cinnamoyl-CoA. We determined the carboxylation efficiency for each enzyme with 
each substrate by quantifying the percentage yield of carboxylated product (compared 
with total product formed, including reduced side product; Figure 1A). We also measured 
the kinetics for each enzyme with each substrate by following the consumption of 
nicotinamide adenine dinucleotide phosphate (NADPH) (Figures 1B and S1; Table S2). 
Based on these parameters, we identified CcrCPAG as the most suited ECR for our 
biocatalytic synthesis strategy, because the enzyme showed the highest carboxylation 
efficiencies, as well as favorable catalytic activities for all substrates tested, with the 
exception of cinnamoyl-CoA. With cinnamoyl-CoA, CcrCPAG showed a reduced 
carboxylation efficiency (57%), as well as a reduced catalytic activity (<0.15 s−1). 
Cinnamoyl-CoA also posed a challenge for other ECRs. While CinF showed higher 
carboxylation efficiencies (74%) compared with CcrCPAG, the enzyme acted even slower 
on this substrate (kcat < 0.11 s−1). AntE and Ndas_0488, on the other hand, displayed 
2-fold higher turnover rates with cinnamoyl-CoA compared with CcrCPAG, albeit at 




Figure 1. Characterization of ECR variants for their substrate promiscuity. (A) Percentage of 
carboxylation product of promiscuous ECRs dependent on the substrate compared with the reduction side 
reaction. Assays contained 100 mM Tris-HCl (pH 8), 100 mM KHCO3, 10 μg mL−1 carbonic anhydrase, 
150 μM NADPH, 75 μM substrate, and 1.5 μg of the respective ECR, quenched with 5% formic acid and 
analyzed by HPLC-MS. (B) kcat of ECRs for all the substrates tested. 
 
Biocatalytic proofreading improved atypical extender unit biosynthesis 
The low carboxylation yields and reduced catalytic activities of ECRs with cinnamoyl-CoA 
posed a problem for the preparative-scale production of benzylmalonyl-CoA. Due to the 
pronounced reduction side reaction of ECRs with cinnamoyl-CoA, most of the substrate 
is converted into phenylpropinoyl-CoA, which represents a “dead-end” product. Thus, we 
sought to employ the concept of biocatalytic proofreading to our biosynthetic strategy 19. 
We reasoned that an efficient regeneration of phenylpropionyl-CoA back into the 
substrate cinnamoyl-CoA should increase the yield of the carboxylation reaction in the 
synthesis assay. Therefore we tested whether the recently described acyl-CoA oxidase 
Acx4 from Arabidopsis thaliana 20 is able to oxidize phenylpropinoyl-CoA into cinnamoyl-
CoA. A detailed kinetic characterization of Acx4 showed that the enzyme is not only active 
with phenlypropionyl-CoA, but accepts many different acyl-CoAs, including the ones that 
are relevant to this study (butyanoyl-, hexanoyl, octanoyl-, and 5-methylhexanoyl-CoA; 
Table 1). In the following, we tested the effect of Acx4 on the AntE-dependent 
carboxylation of cinnamoyl-CoA (Figure 2A). While the control reaction without 
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proofreading enzyme produced only 19% of benzylmalonyl-CoA (Figure 2B), the assay 
containing Acx4 yielded 73% benzylmalonyl-CoA (Figure 2C). The addition of catalase to 
remove the potentially harmful H2O2 produced by Acx4 did not alter the yield of the 
reaction and was therefore not used in further experiments. These results demonstrated 
that Acx4 can be directly added as proofreading enzyme to our biosynthetic assays, and 
that biocatalytic proofreading by Acx4 increases carboxylation product yields by almost a 
factor of 4. In the following we used this route to produce benzylmalonyl-CoA at the 
preparative scale and high purity (Figure S3A). 
 
Table 1. Kinetic characterization of the acyl-CoA oxidase Acx4 
Substrate kcat (s-1) KM (μM) kcat/KM (s−1M−1) 
Butyl-CoA 30 ± 1.1 66 ± 9 (4.5 ± 0.8)·105 
Hexanoyl-CoA 66 ± 2.1 31 ± 3 (2.2 ± 0.3)·106 
Octanoyl-CoA 2.8 ± 0.3 33 ± 5 (8.5 ± 1.3)·104 
5-Methylhexanoyl-CoA 7.2 ± 0.3 32 ± 7 (2.3 ± 0.5)·105 
Phenylpropionyl-CoA 0.21 ± 0.01 12 ± 2 (1.8 ± 0.3)·104 
Assays for butyl-CoA, hexanoyl-CoA, octanoyl-CoA, and 5-methylhexanoyl-CoA were measured at 290 nm 
following the double bond formation using Δε290 = 2.26 cm−1 mM−1. The assay for phenylpropionyl-CoA 
was measured at 308 nm using Δε290 = 16.6 cm−1 mM−1 as determined from the spectra of purified 





Figure 2. Cinnamoyl-CoA carboxylation using the oxidase Acx4 as a proofreading enzyme to recycle 
the side product dihydrocinnamoyl-CoA allows for efficient benzylmalonyl-CoA biosynthesis. (A) 
Scheme of the benzylmalonyl-CoA synthesis reaction containing the proofreading oxidase Acx4. (B and C) 
HPLC analysis of an assay containing 100 mM NaPO4 buffer (pH 8), 100 mM KHCO3, 100 μM cinnamoyl-
CoA, 2 mM NADPH and 5.3 μM AntE. (B) Without proofreading the assay produces mainly the reduced 
side product dihydrocinnamoyl-CoA. HPLC assay analog to B containing additionally 2.6 μM of the 
proofreading enzyme Acx4.(C) Using the proofreading oxidase the assay now mainly yields benzylmalonyl-
CoA. 
 
A convenient one-pot, preparative-scale biosynthesis of atypical extender units 
from acyl-CoAs 
Acx4 was not only useful for biocatalytic proofreading, but also opened an alternative 
route to the synthesis of atypical extender units. We noticed that, when promiscuous Acx4 
and promiscuous CcrCPAG are combined, it becomes possible to synthesize 
alkyl-malonyl-CoAs directly from the corresponding saturated acyl-CoAs. Acyl-CoAs are 
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chemically easily accessible from free CoA and the respective saturated acids 21, 22, which 
are commercially more available and cheaper than their desaturated counterparts. We 
demonstrated this chemo-biocatalytic route in the following. First, we chemically coupled 
free CoA with butanoic-, hexanoic, 5-methylhexanoic-, and phenylpropionic acid in 
preparative scale 22. Then, the individual synthesis assays were lyophilized, resolved in 
buffer (100 mM Tris-HCl (pH 7.5), 100 mM KHCO3) to approximately 1 mM acyl-CoA, and 
incubated with Acx4 (2.4 μM), CcrCPAG (0.8 μM) as well as NADPH (10 mM) for 120 min 
at 30°C (see Figure S2). Progress of the individual reactions was followed by 
high-performance liquid chromatography-mass spectrometry (HPLC-MS) (Figure 3), 
assays were quenched after 120 min, CoA esters were purified via HPLC, lyophilized, 
and yields were determined (Table S3). Butylmalonyl-, hexylmalonyl-, and 
3-methylbutylmalonyl-CoA were produced at yields of >95% from the corresponding acyl-
CoA ester, and around 30% from the used CoA after HPLC purification. Only the 
biosynthesis of benzylmalonyl-CoA did not run to full completion under the chosen 
conditions, even when the concentration of Acx4 and CcrCPAG was increased (Figure 3E). 
Nevertheless, we could use this chemo-biosynthetic route to prepare three alkyl-malonyl-
CoA extender units in the mg scale and at purity >95%, as judged by HPLC-MS (Figure 





Figure 3. One-pot synthesis of atypical polyketide extender units using the acyl-CoA oxidase Acx4 
and the reductive carboxylase CcrCPAG. (A) General reaction scheme. Assays contained 100 mM Tris-
HCl (pH 7.5), 100 mM KHCO3, 10 mM NADPH, approximately 1 mM acyl-CoA from the CDI reaction 
mixture, 2.4 μM Acx4, and 0.8 μM CcrCPAG. (B) HPLC analysis of butylmalonyl-CoA synthesis. (C) HPLC 
analysis of hexylmalonyl-CoA synthesis. (D) HPLC analysis of 3-methylbutylmalonyl-CoA synthesis. (E) 
HPLC analysis of benzylmalonyl-CoA synthesis using 5-fold increased CcrCPAG and 8-fold increased Acx4 






Competition assays verify selectivity-conferring active site residues of PKSs 
The incorporation behavior of PKSs in the presence of a large variety of extender units at 
the same time has been investigated only sparsely so far. This prompted us to utilize our 
set of six diverse alkyl-malonyl-CoAs in PKS competition assays. As model system, we 
used a modified DEBS PKS in vitro model system that produces triketides 18. We first 
tested substrate specificity of the wild-type (WT) modules of the model system in a 
competition experiment containing 1 mM of all extender units; the natural substrate 
methylmalonyl-CoA, as well as the unnatural extender units malonyl-, ethylmalonyl-, 
butylmalonyl-, 3-methylbutylmalonyl-, and hexylmalonyl-CoA. Samples were quenched 
after 60 min incubation at 30°C, and triketides were analyzed by HPLC-electrospray 
ionization-TOF. While the WT modules showed incorporation of ethyl- and butylmalonyl-
CoA, they did not accept 3-methylbutyl-, hexyl-, or malonyl-CoA (Figure 4A), indicating 
that slightly larger extender units are able to enter the WT modules of the triketide model 
system when provided at equal concentrations as the natural extender methylmalonyl-
CoA. This is well in line with earlier reports on the promiscuity of DEBS WT modules 
tested with individual atypical extender units 23.  
 
 
Figure 4. In vitro extender unit promiscuity screen for triketide biosynthesis of the DEBS polyketide 
synthase. The WT systems production was compared with two variants that were altered in the AT domain 
of module 2. Assays contained 1 mM each of the natural extender unit methylmalonyl-CoA (1) and of the 
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atypical malonyl-CoA (2), ethylmalonyl-CoA (3), butylmalonyl-CoA (4), 3-methylbutylmalonyl-CoA (5), and 
hexylmalonyl-CoA (6). Assays were incubated for 60 min and quenched with 5% formic acid. (A) Triketides 
produced by the WT modules of the in vitro DEBS triketide system. (B) Triketides produced by the Y754V 
variant of the AT of module 2 of the DEBS triketide system. (C) Triketides produced by the Q624H variant 
of the AT of module 2. Both variants additionally incorporate 3-methylbutylmalonyl-CoA (5) and 
hexylmalonyl-CoA (6). (D) Scheme of the produced triketides. (E) Model of the AT active site of DEBS 
module 2 generated with SWISS-MODEL24 with the [KS3][AT3] didomain crystal structure (2QO3) as 
template25. Highlighted in purple are serine 652, which carries the malonyl-CoA extender unit, as well as 
tyrosine 754 and glutamine 624, which line the alkyl-malonyl-CoA binding pocket and which were targeted 
by site-directed mutagenesis in this study. (F) Model of the promiscuous AT4 from the reveromycin PKS 
using the same template. Highlighted is the conserved serine that carries the malonyl-CoA extender unit, 
as well as the histidine that replaces the conserved glutamine of methyl-CoA- and ethylmalonyl-CoA-
specific ATs (i.e., Q624 of DEBS AT2). The error bars represent standard deviation of two independent 
assays. 
 
Next, we tested competitive incorporation of atypical extender units into a triketide model 
system with altered selectivity of the AT domain of module 2. To that end we targeted 
Y754, which is located in the YASHS motif of the AT domain, and which was previously 
described to confer methylmalonyl-CoA selectivity 26. We substituted Y754 with valine to 
increase selectivity of the AT toward longer side chains 27. The Y745V showed increased 
incorporation of atypical extender units in the competitive assay, again in line with earlier 
findings (Figure 4B). Having demonstrated that our multi-substrate competition assay can 
be used to screen extender unit selectivity, we decided to target a, to our knowledge, 
sofar uncharacterized glutamine (Q624 in DEBS module 2), which is highly conserved in 
methyl-CoA- and ethylmalonyl-CoA-incorporating ATs. In AT4 of the reveromycin PKS 28, 
which displays relaxed selectivity toward longer and branched alkyl-malonyl-CoA 
extender units, this canonical glutamine is replaced with histidine. The Q624H variant 
showed increased incorporation of atypical extender units in the competitive assay, 
indicating the importance of this residue for substrate selectivity (Figures 4C and 4F). 
Taken together our results demonstrate the potential of the developed synthesis 
route to prepare a set of atypical alkyl-malonyl-CoA extender units that can be used for 
in vitro screening and site-directed mutagenesis of PKSs to assess their substrate 
selectivity. Our chemo-biosynthetic route can be easily extended for the synthesis of a 
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large library of atypical extender units. Along with recently established in vitro polyketide 
systems, this will open the way to characterize large libraries of mutants in the AT domain, 
eventually leading to a detailed understanding of the function of active site residues that 
contribute to substrate selectivity in PKSs. 
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Table S2 (related to Figure 1): kcat and KM of the ECR variants towards the tested substrates. Values 
with yellow background were fitted using substrate inhibition. ND = not determinable, errors are given as 
standard error. 
kcat [s-1]      
 crotonyl-CoA hexenoyl-CoA 5-methylhexenoyl-CoA octenoyl-CoA cinnamoyl-CoA 
CcrCPAG 1.5 ± 0.1 1.4 ± 0.1 0.9 ± 0.1 17 ± 1 0.15 ± 0.01 
CinF 1.84 ± 0.03 1.10 ± 0.04 0.32 ± 0.03 3.5 ± 0.7 0.113 ± 0.003 
AntE 0.81 ± 0.04 1.7 ± 0.1 3.0 ± 0.1 3.1 ± 0.2 0.27 ± 0.01 
Ndas_0488 2.9 ± 0.5 2.8 ± 0.5 1.5 ± 0.1 0.33 ± 0.01 0.28 ± 0.02 
KSE_65530 1.78 ±  0.05 0.50 ± 0.02 0.6 ± 0.1 1.0 ± 0.4 0.03 ± 0.003 
DivR 0.089 ± 0.003 1.0 ± 0.2 0.17 ± 0.01 ND ND 
KM [µM]      
 crotonyl-CoA hexenoyl-CoA 5-methylhexenoyl-CoA octenoyl-CoA cinnamoyl-CoA 
CcrCPAG 525 ± 85 74 ± 10 153 ± 45 75 ± 15 3 ± 2 
CinF 154 ± 10 16 ± 2 53 ± 11 11 ±4 52 ± 6 
AntE 218 ± 31 103 ± 18 125 ± 18 133 ± 18 42 ± 6 
Ndas_0488 38 ± 17 58 ± 17 30 ± 5 45 ± 6 160 ± 35 
KSE_65530 111 ± 8 33 ± 5 36 ± 17 100 ± 60 ND 




Table S3 (related to Figure 3): Yields of extender unit biosynthesis 






Overall yield after 
HPLC purification 
    
butylmalonyl-CoA 57% 99% 27% 
3-methylbutylmalonyl-CoA 50% 100% 36% 
hexylmalonyl-CoA 72% 93% 28% 
benzylmalonyl-CoA 49% 27% - 
 
benzylmalonyl-CoA 




- 8% - 
benzylmalonyl-CoA 
(one pot from cinnamoyl-
CoA) 
















































































































































































































Figure S1 (related to Figure 1 and Table S2): Michaelis-Menten plots of characterized ECR variants 
as well as Acx4. Each point was measured as a triplicate and the error bars are given as standard 






Figure S2 (related to Figure 3) HPLC traces of every step in the synthesis of butylmalonyl-CoA. (A) 
HPLC trace after chemical coupling. Amount of hexanoyl-CoA was assessed by comparing the absorption 
of hexanoyl-CoA at 260 nm to all other absorbing species in the mixture at this wavelength. (B) HPLC trace 
after oxidation and carboxylation of hexanoyl-CoA. Purity was assessed by the absorption of butylmalonyl-
CoA compared to all other absorbing species except of the NADPH/NADP+ peak at 260 nm. (C) HPLC 





Figure S3 (related to Figure 3): Progress of up-scaled benzylmalonyl-CoA synthesis from 
cinnamoyl-CoA. (A) The assay contained 100 mM TrisHCl pH 8, 100 mM KHCO3, 1 mM cinnamoyl-CoA, 
20 mM NADPH, 40 µg mL-1 carbonic anhydrase, 20 µM Acx4 and 2.1 µM CcrCPAG. (B) Extinction 








Figure S4 (related to Figure 3): Purity of all synthesized extender units assessed by HPLC-MS (left 




Key Resources Table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Bacterial Strains 
E.coli BAP1 3 N/A 
E.coli BL21-AI Invitrogen Cat#C607003 
E.coli DH5α NEB Cat#C2987I 
Chemicals 
NADPH Biomol Cat#16156.1 
CoA Roche Cat#10155969 
Crotonic anhydride Sigma Cat#130974 
Propionic anhydride Sigma Cat#240311 
Hexanoic acid Sigma Cat#153745 
Octanoic acid Sigma Cat#C2875 
5-methylhexanoic acid Sigma Cat#CDS003381 
trans-Cinnamic acid Sigma Cat#C80857 
3-phenylpropionic acid Sigma Cat#135232 
CDI Sigma Cat#115533 
Triethylamine Sigma Cat#T0886 
MeOH HPLC grade Roth Cat#KK39.2 
MeCN HPLC grade Roth Cat#HN44.2 
Ammonium formate Fluka Cat#17843 
Kaliumhydrogencarbonate Roth Cat#P748.2 
Tetrahydrofuran Roth Cat#4745.2 
Ethylchloroformate Sigma Cat#185892 
DMF Sigma Cat#227056 
DCM Sigma Cat#270997 
Tris Roth Cat#4855.2 
Protino Ni-NTA agarose Macherey-Nagel Cat#1709 
Recombinant Proteins 
pET16b-CcrCPAG 1 see Table S4 
pET16b-AntE this work see Table S4 
pET16b-Ndas_0488 this work see Table S4 
pET16b-KSE_65530 this work see Table S4 
pET16b-DivR this work see Table S4 
pET16b-Acx4 4 see Table S4 
pET28b-LD(4) (also pBL12) 5 N/A 
pET28b-Strep-LD(4) this work N/A 
pET28b-(5)Mod1(2) (also pBL13) 5 N/A 
pET28b-(3)Mod2TE (also pBL16) 5 N/A 
Software 
eMZed 6 http://emzed.ethz.ch/ 
GraphPad Prism 7 GraphPad Software https://www.graphpad.com/ 
OpenLAB CDS ChemStation Agilent Software https://www.agilent.com/ 
MassHunter Software Agilent Software https://www.agilent.com/ 




Bacterial Strains and Cultivation. All used bacterial strains are listed in the Key 
Resources Table. E.coli DH5α was used for cloning and site-directed mutagenesis. E.coli 
BL21-AI was used for the expression of ECRs and Acx4 and E.coli BAP1 was used for 
expression of DEBS. E.coli was routinely grown in LB at 37°C, protein expressions were 
done in TB at the temperatures described in the Method Details. 
 
Plasmid Construction. The expression plasmid for CinF was a generous gift from Rolf 
Müller2. The expression plasmid for CcrCPAG was previously cloned into pTE-16b using 
NdeI and BamHI, mutations were introduced using the QuickChange Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, USA)1. The antE, divR, Ndas_0488 and 
KSE_65530 were codon optimized and synthesized by the DOE Joint Genome Intitute 
adding an N-terminal 10x His tag and cloned into the backbone pET16b using NcoI and 
XhoI (see Table S4 for complete DNA and protein sequences). 
 
ECR and Acx4 preparation. E.coli BL21 (DE3) (for Acx4 E.coli BL21 AI) were 
transformed with the respective expression plasmid and plated on LB-Agar containing 
100 μg/ml Ampicilin (50 μg/ml Kanamycin for CinF). Pooled colonies of overnight 
inoculated petri dishes were used to inoculate 1 L of TB containing the respective 
antibiotic. The expression culture was incubated at 37°C until an OD600 of 0.8 was 
reached. Cultures for ECR expressions were cooled down to 20°C and induced with 
0.25 mM IPTG and incubated overnight. Acx4 expression cultures were cooled to 30°C 
and induced with 0.25 mM IPTG and 2‰ L-arabinose and incubated for four hours. Cells 
were harvested, resuspended in 50 ml Buffer A (50 mM TrisHCl pH 7.9, 500 mM NaCl) 
and lysed by sonication. Lysates were centrifuged at 42,000 g at 4°C for 45 min. The 
supernatant was then loaded onto a pre-equilibrated 1 mL HisTrap column (GE 
Healthcare) and washed with 15% Buffer B (50 mM TrisHCl pH 7.9, 500 mM NaCl, 
500 mM imidazole) and eluted with 100% Buffer B. The buffer of the purified proteins was 
exchanged into the protein storage buffer (30% glycerol, 150 mM NaCl, 25 mM TrisHCl 
pH 7.9). Protein purity was checked by SDS-gel electrophoresis; concentration of proteins 
was determined spectroscopically at 280 nm using calculated extinction coefficients. For 
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Acx4 the FAD concentration was determined at 450 nm and FAD was added to reach a 
equimolar protein to FAD ratio. Proteins were stored at -20°C. 
 
DEBS protein preparation. The expression plasmids for the in vitro triketide model 
system of DEBS were constructed according to a previously described protocol yielding 
the plasmids pBL12 (here termed pET28b-LD(4); the N-terminal HisTag of pBL12 was 
exchanged for a StrepTag), pBL13 (pET28b-(5)Mod1(2)) and pBL16 (pET28b-
(3)Mod2TE)5. E. coli BAP1 was transformed with expression plasmid, 1 L of TB 
expression culture was grown to an OD600 of 0.7, cooled down to 18°C, induced with 
0.25 mM IPTG and incubated over night at 18°C. Cells producing module 1 and module 2 
were harvested, resuspended in Buffer C (50 mM NaH2PO4 pH 7.6, 450 mM NaCl, 20% 
glycerol), lysed by sonification and centrifuged at 42,000 g at 4°C for 45 min. The 
supernatant was incubated with pre-equilibrated Protino Ni-NTA beads (1 mL resin) for 
1 h. The beads were washed with 5% Buffer D (75 mM NaH2PO4 pH 7.6, 500 mM 
imidazole, 20 mM NaCl, 10% glycerol) and then eluted with 100%. The elution was loaded 
onto a with Buffer E (50 mM NaH2PO4 pH 7.6, 10% glycerol) pre-equilibrated HiTrap Q 
anion exchange column and eluted in a 50 mL NaCl gradient with a final concentration of 
500 mM NaCl. Cells expressing the plasmid yielding the loading domain were 
resuspended in Buffer C, processed as described above and purified over a pre-
equilibrated 1 mL StrepTrap column (GE Healthcare), using 2 mM d-Desthiobiotin 
(Sigma-Aldrich) for elution. Fractions were tested on an SDS-PAGE gel, pooled and 
concentrated with an Amicon Ultra-4 100 kDa (50 kDa for LD(4)) centrifugal filter. A final 
concentration of 20% glycerol was added to the concentrated proteins, their concentration 
was determined spectroscopically at 280 nm and they were stored at -80°C. 
 
Chemical CDI Coupling. CDI (1,1′-carbonyldiimidazole) coupling of carboxylic acids to 
CoA was done according to a previously described protocol7. 42 mg CDI (0.27 mmol, 
4 eq.) was dissolved in 2 mL THF and the acid was added (0.31 mmol, 4.8 eq.; hexanoic 
acid: 38.9 μl, octanoic acid: 49.2 μl, dihydrocinnamic acid: 46.5 μl and 5-methylhexanoic 
acid: 43,5 μl). The reactions were stirred for 1 h at 22°C. 50 mg CoA was dissolved in 
500 μL 1 mL KHCO3 and added to the reaction. The reaction was stirred for another 
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45 min and tested for remaining free thiols using DTNB, then flash frozen in liquid N2 and 
lyophilized overnight. Samples were then dissolved in 1 mL H2O and used for HPLC-
purification or used for desaturation by Acx4 or for direct one-pot biosynthesis of the 
extender units. 
 
Synthesis of cinnamoyl-CoA using ethylchloroformate coupling. Synthesis of 
cinnamoyl-CoA was done by chemically coupling cinnamic acid to CoA according to a 
previously described protocol7. 37 mg trans-cinnamic acid (0.25 mmol, 2 eq.) was 
dissolved in 2 mL DCM, 37 μl trimethylamine (0.26 mmol, 2.1 eq) was added and the 
reaction was stirred at 20°C for 30 min. The mixture was cooled on ice and 24 μl 
ethylchloroformate (0.25 mmol, 2 eq.) was added. The mixture was stirred on ice for 2 h. 
The DCM was evaporated at room temperature and resuspended in 2 mL DMF. 100 mg 
CoA (0.125 mmol, 1 eq.) was dissolved in 300 μL 1 M KHCO3 and added to the mixture 
at 20°C. Completion of the reaction was tested using DTNB, the reaction mixture was 
quenched by adding 500 μL of 50% formic acid, frozen in liquid N2 and lyophilized 
overnight. The sample was dissolved in 2 mL H2O and used for HPLC purification.  
 
Synthesis of malonyl- and methylmalonyl-CoA. Synthesis of malonyl- and 
methylmalonyl-CoA was done according to a previously described protocol7. 20 mg CoA 
(1 eq.), 13.2 mg malonic acid (5 eq.) or 15.2 mg methylmalonic acid (5 eq.) and 70.4 mg 
ATP (4 eq.) were dissolved in 5 mL of 200 mM KHCO3 containing 15 mM MgCl2 and 
3.2 μM MatB. The reaction was incubated at 30°C and completion confirmed with DTNB. 
The mixture was quenched with 5% formic acid and directly used for HPLC purification. 
 
Synthesis of ethylmalonyl-CoA. Ethylmalonyl-CoA was synthesized by chemical 
coupling of crotonic anhydride with CoA followed by the addition of a CcrCPAG, NADPH 
and KHCO3. 10 mg CoA was dissolved in 1 mL 1 M KHCO3.The mixture was cooled on 
ice and 3.2 μl of crotonic anhydride was added and stirred on ice for 30 min. Completion 
of the reaction was tested using DTNB. The reaction mixture was then added to 8 mL of 
250 mM TrisHCl pH 7.5 containing 30 mM NADPH, 250 mM KHCO3 and 100 nM 
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CcrCPAG. The reaction was incubated for 30 min at 30°C, quenched with final 
concentration 5% formic acid and directly used for HPLC purification. 
 
One pot biosynthesis of extender units. The enzymatic desaturation with Acx4 as well 
as the reductive carboxylation was then done using this lyophilized reaction mixture 
without any purification in between. The lyophilized CDI reaction mixture (see above) was 
resuspended in 1 mL of H2O and used directly for the biosynthesis of the extender units. 
A 10 mL assay for extender unit biosynthesis contained 2 mL of 0.5 M TrisHCl pH 7.5 
(final concentration 100 mM), 1 mL of 1 M KHCO3 (100 mM), 500 μL of 200 mM NADPH 
(10 mM), 300 μl of the dissolved CDI reaction mixture (theoretical maximum of 50 mM, 
resulting in an approximate final concentration of 1 mM in the assay), 500 μl of 48 μM 
Acx4 (2.4 μM) and 200 μl of 39 μM CcrCPAG (0.8 μM). The mixture was shaken at 200 rpm 
in a baffled Erlenmeyer flask at 30°C for 120 min. To follow progress of the reaction, 30 μL 
of the reaction mixture were quenched at various time points with the addition of 3 μL of 
50% formic acid and analyzed by analytical HPLC-MS (Figure 3). The reaction was 
quenched after 120 min with the addition of 1 mL of 50% formic acid, centrifuged for 
10 min at 17000 g to remove precipitated protein and then purified via HPLC. The purified 
product was lyophilized, resuspended in water and the final yield of the overall reaction 
and purification was determined by determining the extender unit concentration via 
UV/Vis absorption at 260 nm (calculated as (mol product)/(mol CoA) Table S3). 
 
HPLC purification of acyl-CoA esters. All synthesized CoA-thioesters were purified 
using a 1260 Infinity LC system (Agilent) using a Gemini 10 μm NX-C18 110 Å, 100 x 
21.2 mm, AXOA packed column (Phenomenex). The general protocol used a flow rate of 
25 ml min-1 starting with 5 min of 5% MeOH in 50 mM NH4HCO2 pH 8.2, followed by a 
gradient from 5% to 40% MeOH in 15 min, a 2 min washing step at 95% MeOH and a re-
equilibration step of 3 min at 5% MeOH. Purified CoA-esters were lyophilized and the 
purity was checked using analytical HPLC-MS according to the protocol described for the 




Determination of carboxylation vs. reduction ratio of ECR variants. Assays for the 
determination of carboxylaton vs. reduction contained 100 mM TrisHCl pH 8, 100 mM 
KHCO3, 10 μg mL-1 carbonic anhydrase, 150 μM NADPH, 75 μM substrate and 1.5 μg of 
the respective ECR. The reaction was followed on a Cary-60 UV/Vis spectrometer and 
quenched upon completion with final concentration 5% formic acid. Assays were then 
analyzed on a 1260 Infinity LC system (Agilent) with attached with a 6130 Quadrupole 
LC/MS detector (Agilent) using a Luna 3 μm C18(2) 100 Å, 150 x 2 mm (Phenomenex) 
column with a flow rate of 0.3 ml min-1. For malonyl-, methylmalonyl- and ethylmalonyl-
CoA a gradient starting with 3 min of 5% MeOH in 50 mM NH4HCO2 pH 8.2, followed by 
a gradient from 5% to 25% MeOH over 20 min, a 2 min washing step at 95% MeOH and 
a 3 min re-equilibration step at 5% MeOH. All other samples were run using a gradient 
starting with 3 min of 5% MeCN in 50 mM NH4HCO2 pH 8.2, followed by a gradient from 
5% to 35% MeCN over 20 min, a 2 min washing step at 95% MeCN and a 3 min re-
equilibration step at 5% MeCN. 
 
Spectrophotometric enzyme assays. Enzyme assays were carried out on a Cary-60 
UV/Vis spectrometer (Agilent) using quartz cuvettes (1 mm and 10 mm diameter, 
Hellma). Acx4 characterization was done using 10 mm cuvettes in 100 mM TrisHCl pH 8 
buffer following double bond formation at 290 nm (Δε290 = 2.26 mM-1cm-1) for all 
substrates except for phenylpropionyl-CoA (dihydrocinnamoyl-CoA), which was 
measured at 308 nm (Δε308.=16.4 mM-1cm-1, Figure S2B). ECR characterization for all 
substrates was in 10 mm cuvettes following NADPH consumption at 360 nm in 100 mM 
TrisHCl pH8 buffer containing 100 mM KHCO3 and 500 μM NADPH (Figure S4). 
 
Extender unit incorporation assays. Competition assays to test incorporation of 
extender units into triketides were run at 30°C in 200 mM NaH2PO4 with 2 mM NADPH, 
4 μM epimerase, 0.2 mM propionyl-CoA, 1 mM of each extender unit and 1 μM of LD(4), 
(5)Mod1(2) and one of the (3)Mod2TE variants. Assays were quenched with 5% formic 
acid after 60 min and analyzed via HPLC-ESI-TOF on a 6550 iFunnel Q-TOF LC-MS 
(Agilent) using a 1.8 μm Zorbax SB-C18 column, 50 x 2.1 mm (Agilent) using H2O (A) 
and MeCN (B) both containing 0.1% formic acid. The gradient condition were as follows: 
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0 min 5% B; 1 min 5% B; 6 min 95% B,6.5 min 95% B, 7 min 5% B with a flow rate of 
250 μl min-1. Capillary voltage was set at 3.5 kV and nitrogen gas was used as nebulizing 
(20 psig), drying (13 L-1min,225°C) and sheath gas (12 L min-1, 40°C). MS data were 
acquired with a scan range of 100-1000 m/z. Data were analyzed using MassHunter 
Qualitative Analysis software (Agilent) and eMZed6. 
 
Quantification and statistical analysis. For all Michaelis-Menten plots to determine the 
kinetic parameters of ECRs and Acx4 at least 18 points were measured. The error is 
given as standard deviation (Figure S1 and Table S2). Carboxylation vs. reduction ratios 
were determined in triplicates (Figure 1). One pot extender unit biosynthesis was carried 
out multiple times and a representative progress curve of one assay is shown in Figures 
2 and 3, yields of Table S3 were determined for the shown traces. The in vitro competition 
assays were carried out twice with independently expressed and purified protein batches. 
 
References 
1. Peter, D. M.;  Schada von Borzyskowski, L.;  Kiefer, P.;  Christen, P.;  Vorholt, J. 
A.; Erb, T. J., Screening and engineering the synthetic potential of carboxylating 
reductases from central metabolism and polyketide biosynthesis. Angewandte Chemie 
International Edition 2015, 54 (45), 13457-13461. 
2. Quade, N.;  Huo, L.;  Rachid, S.;  Heinz, D. W.; Müller, R., Unusual carbon fixation 
gives rise to diverse polyketide extender units. Nature chemical biology 2012, 8 (1), 117-
124. 
3. Pfeifer, B. A.;  Admiraal, S. J.;  Gramajo, H.;  Cane, D. E.; Khosla, C., Biosynthesis 
of complex polyketides in a metabolically engineered strain of E. coli. Science 2001, 291 
(5509), 1790-2. 
4. Schwander, T.;  von Borzyskowski, L. S.;  Burgener, S.;  Cortina, N. S.; Erb, T. J., 
A synthetic pathway for the fixation of carbon dioxide in vitro. Science 2016, 354 (6314), 
900-904. 
5. Lowry, B.;  Robbins, T.;  Weng, C. H.;  O'Brien, R. V.;  Cane, D. E.; Khosla, C., In 
vitro reconstitution and analysis of the 6-deoxyerythronolide B synthase. J Am Chem Soc 
2013, 135 (45), 16809-12. 
6. Kiefer, P.;  Schmitt, U.; Vorholt, J. A., eMZed: an open source framework in Python 
for rapid and interactive development of LC/MS data analysis workflows. Bioinformatics 
2013, 29 (7), 963-964. 
7. Peter, D. M.;  Vögeli, B.;  Cortina, N. S.; Erb, T. J., A chemo-enzymatic road map 






Understanding Substrate Selectivity of Phoslactomycin Polyketide 
Synthase by Using Reconstituted in vitro Systems 
 








Understanding substrate selectivity of phoslactomycin 
polyketide synthase using reconstituted in vitro systems 
Kyra Geyer[a], Srividhya Sundaram[a], Peter Sušnik[b], Ulrich Koert[b], Tobias J. Erb*[a], [c] 
 
[a]Department of Biochemistry and Synthetic Metabolism; Max Planck Institute for Terrestrial Microbiology, 
Karl-von-Frisch-Str. 10, D-35043 Marburg, Germany, toerb@mpi-marburg.mpg.de [b]Department of 
Chemistry, Philipps-University Marburg, Hans-Meerwein-Str. 4, D-35032 Marburg, Germany [c]LOEWE 
Center for Synthetic Microbiology (Synmikro), Karl-von-Frisch-Str. 16, D-35043 Marburg, Germany. 
*Corresponding author: toerb@mpi-marburg.mpg.de 
 
ChemBioChem 2020, 21, 1-7 
Author contributions: K.G. and T.J.E conceived the project. K.G., designed and 
performed experiments and analyzed the data. S.S performed expression experiments. 
P.S. synthesized the SNAC ester derivatives. K.G. and T.J.E. wrote the manuscript with 
contributions from all authors. 
 
Abstract: Polyketide synthases (PKS) use simple extender units to synthesize complex 
natural products. A fundamental question is how different extender units are 
site-specifically incorporated into the growing polyketide. Here we established 
phoslactomycin (Pn) PKS that incorporates malonyl- and ethylmalonyl CoA as an in vitro 
model to study substrate specificity. We combined up to six Pn PKS modules with different 
termination sites for the controlled release of tetra-, penta- and hexaketides and 
challenged these systems with up to seven different extender units in competitive assays 
to test for specificity of Pn modules. While malonyl-CoA modules of Pn PKS exclusively 
accept their natural substrate, the ethylmalonyl-CoA module PnC tolerates different 
α-substituted derivatives, but discriminates against malonyl CoA. We show that the ratio 
of extender transacylation to hydrolysis controls incorporation in PnC, explaining 











Polyketides are a class of natural products with high structural diversity but common 
biosynthetic logic. They are synthesized by polyketide synthases (PKSs) from simple acyl 
and (alkyl)malonyl CoA-based building blocks. The structure of the product is determined 
by the type and location of catalytic domains in the assembly line, while structural diversity 
of the backbone arises from the choice of extender unit, extent of reduction and stereo 
centers installed during biosynthesis 1, 2. The three major extender units incorporated in 
polyketides are malonyl-, methylmalonyl-CoA and to a lesser extent ethylmalonyl-CoA. 
While it is generally believed that the acyltransferase (AT) domains control extender unit 
incorporation, recent reports have shown that these domains are more promiscuous than 
initially assumed. For example AT5 of monensin accepts methyl- and ethylmalonyl-CoA 
in the natural system, but experiments showed that also propargyl- and butylmalonyl-CoA 
are accepted 3, 4. Research on the 6-deoxyerythronolide B PKS (DEBS), a 
well-established model system, revealed an intrinsic promiscuity of the ATs of module 2, 
module 3 5 and module 6 6. Promiscuous AT domains were also observed in the 
structurally highly similar pikromycin PKS (module 5 and module 6 7, 8). However, to 
fundamentally understand how extender unit selectivity in PKS is achieved other, more 
diverse model systems are required. Especially, since the well-studied DEBS PKS does 
not need to distinguish between different extender units, because only methylmalonyl-
CoA is incorporated into the assembly line. Here, we focused on phoslactomycin (Pn) 
PKS, a modular type I PKS from Streptomyces platensis 9, 10. Pn PKS is composed of a 
loading module selecting cyclohexanecarboxyl-CoA (1) and seven extending modules of 
which five incorporate malonyl-CoA (2) and two incorporate ethylmalonyl-CoA (3b) 
(Scheme 1). This makes Pn PKS, in comparison to methylmalonyl-CoA specific DEBS 
PKS, an excellent model to study how extender unit selectivity is controlled at different 




Scheme 1. Phoslactomycin polyketide synthase Pn PKS. ACP=acyl carrier protein; 
AT=acyltransferase; DH=dehydratase; KR=ketoreductase; TE=thioesterase; 1=cyclohexanecarboxyl-CoA; 
2=malonyl-CoA; 3=(2S)-ethylmalonyl-CoA; 10=phoslactomycin polyketide backbone, 11=bioactive 
phoslactomycin derivatives; R=isobutyloxy; isovaleryloxy; 4-methylcaleryloxy; cyclohexylcarbonyloxy; 





Results and Discussion 
We aimed at establishing different Pn-based minimal model systems for the production 
of tetra-, penta- and hexaketides to study promiscuity and selectivity, in particular of the 
3b incorporating PnC_AT. To that end, we expressed PnA-PnD as individual proteins in 
E. coli BAP1 7, 8, 11, 12 (Figure S1). For PnA production, we tested five different 
transcription start sites (PnAV1-PnAV5, Scheme 2), due to insolubility upon expression of 
the full-length annotated PnA protein. Variant PnAV4 resulted in highest protein 
expression and solubility. To enable polyketide release in the tetra-, penta- and 
hexaketide systems, we used the chain releasing thioesterase (TE) from DEBS to create 
chimeric PnB-TEDEBS, PnC-TEDEBS and PnD-TEDEBS constructs 8, 13, 14 (DNA sequence 
information in SI). 
E. coli BAP1 encodes for a functional phosphopantetheinyl (Ppant) transferase. 
Yet, phosphopantetheinylation highly varied across individual Pn acetyl-carrier proteins 
(ACPs) (Table S1). While PnC_ACP was fully converted to holo-ACP (96%), only 26% of 
PnB_ACP1 was present in the holo-form. Analysis revealed one gene from the 
4’-phosphopantetheinyl transferase superfamily (Npt, OSY40025) with low homology to 
Sfp (16.1% sequence identity) in the genome of S. platensis. We expressed the protein 
in E. coli BL21 (DE3) and demonstrated that Npt serves as a bona fide Ppant transferase 
that is able to activate apo-Pn_ACPs (Figure S2). We further added purified Npt to all in 
vitro assays to ensure the full conversion of all Pn proteins to their holo-form. 
One-pot reaction mixtures of PnAV4 and PnB-TEDEBS (tetraketide system), PnAV4, 
PnB and PnC-TEDEBS (pentaketide system), PnAV4, PnB, PnC and PnD-TEDEBS 
(hexaketide system), incubated with their natural substrates resulted in production of 
respective polyketide derivatives, as analyzed by high resolution LC-MS. Enzymatic 
production of these derivatives was additionally verified using 2-C13 labelled malonyl-CoA 
(Figure S3, Figure S4 and Figure S5). A product corresponding to a dehydrated 
tetraketide (m/z 206.1307, formula C13H18O2) is the exclusive product found in tetraketide 
assays. In pentaketide assays, a more complex product spectrum was observed, with 
m/z 258.1620 corresponding to a pentaketide of formula C17H22O2 as the main product.  
Various masses were found in hexaketide assays that correspond to different products 
with m/z 284.1776 corresponding to hexaketide of formula C19H24O2 as the main product 
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(Scheme 2). Based on the combined information from the high resolution mass 
spectrometer and isotopic labeling, we propose structures for the individual masses 
detected, and provide an explanation for their generation in Figure S6. Altogether, our 
analysis demonstrated that the Pn PKS enzymes are functional in vitro and can be 





Scheme 2. In vitro reconstitution of Pn PKS. Structural model of PnA loading AT with the alternative 
transcription start sites V1 to V5 highlighted in red. S. platensis endogenous Ppant transferase Npt and 
CoA-SH were used to ensure full conversion into the corresponding holo-PKS in vitro. 1, 2 and 3b are the 
natural substrates of Pn PKS. Termination of the polyketide production with PnB-TEDEBS, PnC-TEDEBS or 
PnD-TEDEBS is expected to yield the depicted tetra- (4), penta- (5b) or hexaketide (6b). Mass spectrometric 
analysis detected derivatives thereof indicating dehydrations and oxidations. A detailed discussion of the 
individual masses, the corresponding putative products and their generation is provided in Figure S6.  
 
Successful reconstruction of the first six modules of Pn PKS allowed us to assess the 
substrate tolerance of the system with seven different extender units (2, 3a-f). In these 
assays, we bypassed PnAV4 by using the N-acetylcysteamine (SNAC) analogue of the 
diketide product (7, see SI for synthesis). We tested substrate tolerance across the tetra-, 
penta- and hexaketide systems employing three different strategies. In strategy 1, we 
used 7, 2 (malonyl-CoA) and one of the six α-substituted extender units (3a-3f) to test if 
substrates other than ethylmalonyl-CoA (3b) are incorporated. In strategy 2, we used 7, 
2, 3b and one additional extender unit (3a, 3c-3f), to set the incorporation of 3b in direct 
competition to an alternative non-native extender unit. In strategy 3, we used 7, 2, and all 
six α-substituted extender units in parallel (3a-f) to allow identification of the preferred 
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Strategy 1: (non-competitive)
7 + 2 + 3 (a/b/c/d/e/f)
Strategy 2: (single competitive)
7 + 2 + 3b + 3 (a/c/d/e/f)
Strategy 3: (multiple competitive)
7 + 2 + 3 (a,b,c,d,e and f)
PnB PnC-TEDEBS
PnC PnD-TEDEBS
module 2 module 3 module 4
module 4 module 5
PnB
module 2 module 3
PnB-TEDEBS
module 2 module 3
tetraketide 4 pentaketide 5 hexaketide 6
 
Scheme 3. Pn PKS in vitro characterization. 7 diketide product of PnAV4 as SNAC thioester analogue, 2 
malonyl-CoA, 3 (2S)-acyl-malonyl-CoA derivatives with residues marked in orange: a methyl-, b ethyl-, c 
butyl-, d 3-methylbutyl-, e hexyl-, f benzylmalonyl-CoA. Polyketide production is terminated with 
PnB-TEDEBS, PnC-TEDEBS or PnD-TEDEBS to produce 4, 5 and 6, respectively. 
 
Using strategy 1 and strategy 2 with the tetraketide system, we observed exclusive 
incorporation of 2, as indicated by product analysis. No alternative extender unit was 
accepted, indicating exquisite selectivity by PnB. In the pentaketide system, incorporation 
of all six α-substituted extender units 3a-3f was observed, while 2 was not incorporated 
at the position of PnC (Figure S4). This demonstrates substrate tolerance of PnC towards 
α-substituted extender units, but at the same time strong discrimination against 2. More 
specifically, similar amounts of 5b, 5c, 5d and 5e were detected in the pentaketide 
system, when testing substrate tolerance with strategy 1 (Figure 1A). Products of 3a 
incorporation showed less intensity and products of 3f incorporation were detectable in 
traces. In strategy 2, when we put incorporation of 3b (natural substrate) in direct 
competition to another extender unit, we again observed tolerance of PnC towards 
90 
 
medium chain extender units (3b-d), and discrimination against short (3a) and long chain 
(3e and 3f) extender units. With strategy 3, the trend increased further towards preferred 
incorporation of 3b (natural substrate) and 3c by the pentaketide system. 
 
 
Figure 1. Relative amounts of pentaketides and hexaketides in competition assays. Ion count of each 
product is set relative to 5b or 6b. 5* or 6* indicate incorporation of 2 by PnC. Given is the mean of minimum 
three biological replicates, with each two technical replicates (pentaketide assays) and the mean of three 
biological replicates, with each two technical replicates (hexaketide assays). 
 
Having demonstrated that PnC contains a highly promiscuous AT and is able to form 
different pentaketides by incorporation of 3a-3f, we asked, whether PnD is able to accept 
and process the unnatural pentaketides. We used strategy 1 and 2 to study substrate 
tolerance of the reconstituted hexaketide system. When only one α-substituted substrate 
is available, 6a-6e but not 6f were formed (Figure 1B, Figure S5). Also, we did not detect 
multiple incorporations of non-native extender units, indicating that PnC is the only entry 
point of non-native extender units. With strategy 2, natural product 6b became the main 
product. This demonstrated that Pn PKS is generally flexible for incorporation of unnatural 
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extender units at the level of PnC (Figure 1A, strategy 1) but that in presence of the 
natural substrate a preference for the latter exists (Figure 1B, strategy 2). 
When comparing the product profile of strategy 2 to strategy 1 in hexaketide 
assays, we observed that relative product formation decreased with increasing size of the 
side chain. For 6a we observed a decrease of only 26%, whereas for 6c, 6d and 6e the 
relative decrease increased between 72% and 83%. Furthermore, compared to 5a-5b 
and 6a-6b that were detected as reduced product, alongside oxidized products (Figure 
S6, Table S2), 5c-5f and 6c-6e were exclusively found as the non-reduced products, 
indicating the polyketide is not fully processed by subsequent domains after incorporation 
of the non-native, longer extender unit, which is in line with earlier reports 8. Taken 
together this indicates a selection by PnD for pentaketides with shorter site chains, either 
due to restrictions in the KS active site and/or by preferred reduction (and further 
processing) of those pentaketides. 
Next, we wanted to study the specificity of acyl transfer at single domain level. To 
that end, we aimed at measuring kinetic parameters for transacylation and hydrolysis in 
ketosynthase-AT (KS-AT) didomains. In the commonly used assay, these kinetic data are 
collected by coupling CoA-SH release by the AT domain to production of succinyl-CoA 
by a commercially available α-ketoglutarate dehydrogenase complex (α-KGDH) 12, 15, 16. 
However, we observed varying apparent (app.) AT activity that was dependent on the 
α-KGDH batch used. We therefore developed a steady state kinetic assay based on 
purified E. coli succinyl-CoA ligase complex SucC/SucD, to minimize AT-inhibition 
(Scheme S1). In this assay, when the acyl-residue is transferred to the AT, free CoA-SH 
is released. The free CoA-SH is coupled to succinate via SucC/D, whereby ADP is 
released. ADP production is subsequently coupled to NADH consumption via pyruvate 
kinase/lactate dehydrogenase. Thus, the release of CoA-SH is coupled to NADH 
consumption, which can be spectrophotometrically measured and quantified. 
With the SucC/SucD-based assay we determined kinetic parameters of 
PnB_KS-AT1, PnB_KS-AT2, PnC_KS-AT and PnD_KS-AT for hydrolysis and 
transacylation (Table S3, Figure S7). As negative control AT catalytic knockouts were 
used. All ATs described to incorporate 2 (PnB module 2, module 3 and PnD), showed 
hydrolysis and transacylation activity only for their natural substrate, which is in line with 
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our in vitro experiments in the reconstituted system. These measurements were 
independently confirmed by mass spectrometric analysis of acylated ACPs, in which we 
exclusively detected malonyl-ACP formation (Table S1, Table S4). All three ATs showed 
comparable hydrolysis rates at an app. kcat of approx. 3 min-1 and an app. KM between 
4 µM to 11 µM. Rates for transacylation were between 10- to 35- fold higher (app. kcat of 
28 min-1 - 140 min-1) at 2.5 to 7.7 fold higher catalytic efficiency (Table S3). 
In contrast, PnC_KS-AT showed pronounced promiscuity and, except for 3f, 
hydrolytic activity was detected with all tested extender units, including 2 which is not 
incorporated into the pentaketide (Table 1). The app. kcat and in particular the app. KM 
strongly differed, depending on the tested substrate. Interestingly, the app. kcat for 2, 3a-
3e differed only by a factor of four, ranging between 0.4 min-1 to 1.4 min-1, while strong 
differences were observed in the app. KM, that varied by a factor of 12 between the 
different substrates, ranging from 6 µM to 73 µM. Transacylation rates of PnC_KS-AT 
could not be measured with the SucC/SucD-based assay, due to high background 
activity, which could not be reduced even by further purification of the enzymes. Thus, we 
determined the app. kcat for transacylation for 2 and 3b-3e by an HPLC-based assay 
(Figure S8, Figure S9 and Figure S10). PnC_KS-AT was able to transfer all tested 
substrates, however at lower rates compared to transacylation rates of PnB_KS-AT1, 
PnB_KS-AT2 and PnD_KS-AT. The highest transacylation rates of PnC_KS-AT were 
observed for its natural substrate 3b (4±0.1 min-1) The slightly longer substrates 3c and 
3d were transacylated at approximately 7- to 12- fold and 2 and 3e at approximately 100- 
to 80- fold lower rates, respectively, suggesting that transacylation (more than hydrolysis) 
is a crucial factor for incorporation by PnC. We independently confirmed these findings 
by mass spectrometric analysis of acylated PnC_ACP (Table 1, Table S4).  
Overall, our kinetic data show that malonyl-CoA specific domains (PnB_KS-AT1, 
PnB_KS-AT2, and PnD_KS-AT) exclusively transfer malonate to their cognate ACP and 
neither show transacylation nor hydrolysis for non-native substrates. PnC_KS-AT on the 
other hand transfers all tested substrates onto its cognate ACP, including 2 which is not 
incorporated into the polyketide product. PnC_KS-AT also displays hydrolytic activity 
against all substrates, indicating that in the natural context selectivity is achieved by the 




Table 1. app. KM and app. kcat values for hydrolysis and transacylation by PnC_KS-AT 
Hydrolysis 
Substrate KM [µM] kcat [min-1] kcat/ KM 
2 53±41 0.6±0.15 0.01 
3a 73±33 1.4±0.3 0.02 
3b 6±1.8 0.9±0.06 0.15 
3c 6.2±1.4 0.7±0.04 0.11 
3d 20±6.7 0.8±0.08 0.04 
3e 19±15.5 0.4±0.08 0.02 
3f -[a] - - 
Transacylation 
Substrate KM [µM] kcat [min-1] kcat/ KM 
2 n.d[b] 0.04±0.002 - 
3a n.d n.d - 
3b n.d 4±0.1 - 
3c n.d 0.6±0.03 - 
3d n.d 0.3±0.07 - 
3e n.d 0.05±0.001 - 
3f n.d - - 






In this study, we successfully reconstituted the first six modules of phoslactomycin PKS 
as a new in vitro model system to assess how different extender units are selectively 
recruited within one PKS system. Establishing this model system required production of 
various soluble and functional proteins, as well as their respective substrates. C-terminal 
chimeric fusions of DEBS_TE to PnB, PnC and PnD enabled production of different 
polyketide products ranging from tetra- to hexaketide (Scheme 2), to study incorporation 
selectivity of natural and non-native extender units in non-competitive and competitive 
assays.  
Experiments on substrate selectivity show that PnB module 2, module 3 and PnD 
exclusively accept 2, even in the presence of alternative extender units, demonstrated by 
in vitro reconstitution and kinetic assays. PnC on the other hand shows a high substrate 
tolerance towards α-substituted malonyl-CoA derivatives but does not accept 2 itself, 
which is present in the cell. Strikingly PnC mainly excludes substrate 3a, while it readily 
accepts its natural substrate 3b and longer derivatives (3c-e) (Figure 1A, strategy 1). 
Competition assays show that PnC prefers ethyl-residues over shorter (methyl-) and very 
long (hexyl-) residues, while in competition PnC does not have a pronounced selectivity 
against linear and branched medium chain lengths (butyl- and 3-methylbutyl residues) 
(Figure 1A, strategy 2, 3). The same competition assays also indicate that PnD readily 
accepts non-natural polyketide intermediates from PnC_ACP, with a preference of shorter 
side chains at C-2 position (Figure 1B). The preference of PnD for short side chains at 
C-2 position could be located at the KS and ketoreductase, as previously hypothesized 8. 
Thus, the observed trends in product distribution are the result of medium chain length 
preference of PnC during extender unit incorporation and selection for short(er) side 
chains at the C-2 position of the polyketide by PnD during downstream processing.  
Detailed kinetic analysis shed light on the question of how PnC discriminates 
against malonate. Hydrolysis rates of PnC_KS-AT between different substrates differ only 
by a factor of four. Note that hydrolysis of natural substrate 3b is even two-fold higher 
than for 2. Assuming saturating levels of malonyl-CoA on PnC_KS-AT this suggests that 
substrate preference is guided by differences in transacylation rates of 3b and 2. 
Transacylation of the natural substrate 3b is 100-fold higher than 2. The relative 
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transacylation to hydrolysis rate still shows a 63-fold preferred reaction for 3b (4.4) versus 
2 (0.07). The relative transacylation to hydrolysis rate also explains incorporation of the 
other substrates in following order 3c (0.82), 3d (0.41) and 3e (0.142) that we observed 
in the pentaketide system. While the hydrolytic side reaction is often referred to as a 
proofreading function7, it is apparently not the hydrolysis per se in PnC_KS-AT that 
discriminates against a substrate, but rather the efficiency of transacylation. Apparently, 
PnC_KS-AT was selected against transacylation of malonyl-CoA, which is of importance 
in natural context in respect to formation of the correct product. The observed flexibility in 
transacylation (and incorporation) of non-native extender units in PnC_AT and its 
downstream processing is probably due to the fact that these are not present in the natural 
context.  
Substrate selectivity is also linked to unique sequence motifs. A common motif in 
AT domains is GX1SX2G around the active site serine, whereas X1 mostly is a histidine 17. 
Another important motif is a highly conserved HAFH motif in the binding pocket of 
malonyl-CoA specific domains. Ethylmalonyl-CoA specific ATs show a less well 
preserved motif at this position, generally XAGH, with X being F, T, V or H 18. On both 
positions PnC_AT shows unique sequence motifs, with a GSS and a CASH motif in the 
acyl-CoA binding pocket (Figure S11). These sequence differences provide strong 
arguments for the observed substrate tolerance and render PnC_AT a highly interesting 
enzyme for further functional investigations. 
In sum, we established an additional, complementary in vitro PKS system for the 
detailed study of substrate specificity. This system will hopefully enable the testing of 
existing hypotheses on extender substrate selectivity and facilitate PKS engineering by 
offering the possibility of site specific incorporation of alternative extender units to create 
novel polyketide structures in the future. 
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Figure S1: SDS gel of enzymes used in this study. (A) PnAV4 (251.75 kDa), PnB (354.42 kDa), PnB-TE 
(374.95 kDa), PnC (176.81 kDa), PnC-TE (198.99 kDa) and PnD-TE (221.18 kDa) after affinity purification 
and size exclusion. (B) Npt (25.78 kDa) after affinity purification, SucC (43.56 kDa) and SucD (31.94 kDa) 
after affinity purification and size exclusion. (C) PnB_KS-AT1 (97.19 kDa), PnB_KS-AT2 (96.76 kDa), 
PnC_KS-AT (101.32 kDa), PnD_KS-AT (100.57 kDa) and (D) PnB_ACP1 (12.77 kDa), PnB_ACP2 






Figure S2: Full conversion of Pn_ACPs to holo-ACPs. Npt from Streptomyces platensis is able to fully 
convert apo-Pn_ACPs to holo-Pn_ACPs. (A) PnB_ACP1, (B) PnB_ACP2, (C) PnC_ACP, (D) PnD_ACP. 
For no reaction residual apo-Pn_ACPs could be detected. 100 µM ACP was incubated with 300 µM CoA, 








Figure S3: Extracted ion chromatograms from assays with PnAV4 and PnB (tetraketide system), PnAV4, 
PnB, PnC-TEDEBS (pentaketide system) and PnAV4, PnB, PnC and PnD-TEDEBS (hexaketide system). 
Products of the tetraketide and pentaketide system are three times labelled, upon incorporation of 2-C13 
labelled malonyl-CoA, products of the hexaketide system four times. The tetraketide product (4) can only 
be found as in the dehydrated form (m/z [M+H]+ 207.1380). Three masses are shown for the pentaketide 
product (m/z [M+H]+ 277.1798, [M+Na]+ 299.1618 and as m/z [M+H]+ 259.1693) (5b.2, 5b.4, Figure S6). 
For the hexaketide one mass corresponding to the oxidized, dehydrated (6b.5, Figure S6) ion is shown as 







Figure S4: Mass spectrometric data of pentaketide production. (A) Overlaid extracted ion 
chromatograms of 5a, 5b, 5c, 5d and 5e from single competition assays. (B) All assays were run with either 
malonyl-CoA (red) or 2-C13 malonyl-CoA (black). This resulted in double labeled pentaketide (PnB module 
1 and module 2 incorporate malonyl-CoA). Searched for and shown are the masses of 5a-e.2 and 5f.4 
(Figure S6). (5a: m/z 263.1645 and m/z 265.1702, 5b: m/z 277.1798 and m/z 279.1859, 5c: m/z 305.2111 
and m/z 307.2174, 5d: m/z 319.2268 and m/z 321.2331, 5e: m/z 333.2424 and m/z 335.2487, 5f: m/z 







Figure S5: Mass spectrometric data of hexaketide production. (A) Overlaid extracted ion 
chromatograms of 6a, 6b, 6c, 6d and 6e from single extender unit assays. (B) All assays were either run 
with malonyl-CoA (red) or 2-C13 malonyl-CoA (black). This resulted in three time labeled hexaketide (PnB 
module1 and module 2 and PnD incorporate malonyl-CoA). Searched for and shown are the masses of 6a-
e.6 (Figure S6). (6a: m/z 271.1693 and m/z 274.1784, 6b: m/z 285.1849 and m/z 288.1941, 6c: m/z 














Figure S6: Product spectrum of phoslactomycin in vitro assays. Panel (A), (B) and (E) show the 
proposed structures of the tetra-, penta- and hexaketide products of the reconstituted phoslactomycin in 
vitro polyketide system. Panel (C), (D), (F) and (G) show the products that are expected when respective 
KR are catalytically knocked out. Marked in blue, by the formula and retention time (RT), are the masses 
that were detected in the mass spectrometric measurements, as well as their derived structures. The 
structures were derived from the proposed biosynthetic pathway for the phoslactomycin polyketide 
backbone1.  
Tetraketides 
(A) After synthesis the tetraketide 4 is bound to the ACP of PnB_ACP2, which can be released as an acid 
(4). Tetraketide 4 can only be found as the dehydrated product 4.1. Strong conjugation by the double bonds 
destabilize the hydroxyl group at C-3 and 4.1 is formed. Alternatively, DEBS_TE forms a four membered 
lactone ring, although such a function was never reported for DEBS_TE.  
Pentaketides 
(B) The linear pentaketide 5.b is bound to PnC_ACP after synthesis. However, 5.b cannot be detected by 
mass spectrometric analysis, pointing towards lactonization by DEBS_TE and/or spontaneous 
lactonization, resulting in 5b.1. Electron spray ionization (ESI) during mass spectrometric measurements 
causes dehydration, forming 5b.3, with the same RT as 5b.1. The hydroxyl group at C-3 of 5b.1 is prone 
to oxidation in solution, leading to the expected formation of 5b.2. Further dehydration by ESI leads to 
formation of 5b.4, with the same RT as 5b.2. An alternative route for the synthesis of 5b.2 would be a 
(partially) inactive PnC_KR. However, since 5b.1 correspond to the reduced pentaketide, it seems rather 
likely that PnC_KR is fully functional and that 5b.2 is generated by subsequent oxidation of the fully reduced 
pentaketide. 
(C) In the catalytic knock out of the KR of PnB module 2, PnBY3074F, the C-5 of the pentaketide should carry 
a ketone group instead of a hydroxyl-group, 5b.5 is bound to PnC_ACP. Keto groups are prone to 
enolization, enabling the formation of product 5b.6, either by releasing itself by ring formation from the 
thioester linkage on the ACP or catalyzed by DEBS_TE. Due to the loss of water by mass spectrometric 
analysis 5b.4 can also be measured in reaction with PnBY3074F.  
(D) Product 5b.7, the product of assays with PnC_KR catalytic knockout PnCY1367F, is bound to PnC_ACP 
and is the expected product if the free acid is released by DEBS_TE. 5b.7 can be detected in mass 
spectrometric analysis. This product can form the lactone 5b.2 (as discussed in panel B) by spontaneous 
lactone ring formation, or catalyzed by DEBS_TE on PnC_ACP. Formation of 5b.4 can be explained by 
ESI-induced dehydration.  
Hexaketides 
(E) The linear hexaketide 6b is bound to PnD_ACP, the acid 6b and product 6b.1 cannot be distinguished 
by mass, therefore generation of the double bond by PnD_DH cannot be verified. Product 6b.1 could be a 
result of spontaneous and/or DEBS_TE catalyzed lactone ring formation prior to dehydration by PnD_DH. 
The following product 6b.4 could result from 6b.1 by oxidation in solution. An alternative for the formation 
110 
 
of 6b.4 is the release from the thioester on PnD_ACP by ring formation of the unreduced hexaketide 6b.7, 
catalyzed by DEBS_TE or spontaneous ring formation. The product 6b.4 can both dehydrate in water 
(indicated by shift in RT) and by mass spectrometric measurement (same RT), forming 6b.5. Formation of 
6b.6 can be explained by ESI-induced dehydration.  
(F) Linear hexaketide 6b.8 with a keto group at C-7 as the product of assays containing PnBY3074F is bound 
to PnD_ACP but cannot be found as an acid in solution, however a mass corresponding to 6b.9 can be 
detected. 6b.9 corresponds to a hexaketide where PnD_DH did not dehydrate the hydroxyl group at C-3, 
probably due to premature release by DEBS_TE. Following products 6b.10, 6b.11 and 6c.12 corresponding 
to lactone ring formation, oxidation or dehydration by ESI (reactions that were observed with the 
pentaketide) cannot be found. However masses corresponding to product 6b.5 can be found additionally 
to 6b.9. 
(G) Product 6b.13 as the expected product of assays containing PnCY1367F would be bound to PnD_ACP 
but cannot be found by mass spectrometric analysis. Like observed before, the hexaketide could be 
released by pyrone ring formation of the thioester with the enolized ketogroup at C-5, prior to dehydration 
by PnD_DH. Subsequently water can be lost to form 6b.15 By ESI measurement another water is lost and 
6b.6 is formed (same RT as 5b.15).  
 
Conclusion to Figure 5: Altogether, our analysis demonstrated that the Pn PKS 
enzymes are functional in vitro and can be combined stepwise to produce tetra- penta- 
and hexaketide Pn polyketide derivatives. In all cases, we detected dehydrated and 
oxidized derivatives of the expected polyketides as the main products and are able to 
propose structures to the calculated molecular formula. To improve formation of the linear 
hexaketide, we created a catalytic knockout of the PnC_KR (PnCY1367F). Combining 
PnCY1367F with PnD TEDEBS did not improve linear hexaketide formation but led to the 
formation of 6b.15 (similar spontaneous ring formation is also observed in other PKS 2). 
In hexaketide assays, we observed premature release of pentaketide, pointing to 
autocatalytic lactonization. Lactonization and self-release has also been observed for the 
DEBS system 3. To circumvent autocatalytic release and increase hexaketide formation, 
we decided to remove the hydroxyl group attacking the thioester that is installed by the 
KR in PnB module 2 (PnBY3074F). This resulted in production of 6b.9, albeit total 
hexaketide production was reduced (18 ± 0.5% residual production). Similar deleterious 
effects of KR mutants have been observed in other PKS systems 4. These experiments 
allowed us to establish and characterize the behavior of the Pn system for subsequent 




Figure S7: Michaelis Menten plots of KS-AT hydrolysis and transacylation measured with the 
SucC/SucD based steady state kinetic assay. Each reaction was measured in three technical replicates. 
(A) PnB_KS-AT1, (B) PnB_KS-AT2, (C), PnC_KS-AT (substrates used are malonyl- (2), methylmalonyl- 














Figure S8: HPLC UV-vis traces of PnC_ACP loaded by PnC_KS-AT (indicated with arrows) with the 
tested extender units. Incubation time of 5 µM PnC_KS-AT, 100 µM PnC_ACP and 300 µM CoA substrate 
was 2 h, except for ethylmalonyl-CoA (5 min incubation time) Reaction was run at 25°C. A shift of retention 
time can be observed for all substrates, except methylmalonyl-PnC_ACP, which elutes at the same 
retention time as holo-PnC_ACP. Substrates used were malonyl- (2), methylmalonyl- (3a), ethylmalonyl- 





Figure S9: HPLC UV-vis analysis for PnC_KS-AT transacylation rate. The three colors represent three 
technical replicates. Slopes from the linear increase were used for the calculation of kcat. Relative amount 
of acyl-ACP is given on the y-axis. Substrates used are (A) ethylmalonyl-CoA, (B) malonyl-CoA, (C) 
butylmalonyl-CoA, (D) 3-methylbutylmalonyl-CoA, (E) hexylmalonyl-CoA. For ethylmalonyl-ACP and 
butylmalonyl-ACP a decrease of acyl-ACP can be observed after 25 min and after 150 min, respectively. 
Note also the maximum conversion reached in the transacylation assay varies between approx. 70% for 
ethylmalonyl-, butylmalonyl-, 3-methylbutylmalonyl-ACP and approx. 40% for malonyl-ACP. Transacylation 
rate could not be determined for methylmalonyl-CoA, due to same retention time of holo-PnC_ACP and 






Figure S10: HPLC based transacylation assay to confirm results of SucC/SucD assay. For the 
measurement of the kcat of transacylation by PnC_KS-AT the SucC/SucD based assay could not be used 
due to high background activity, which could also not be reduced by repeated size exclusion 
chromatography of the used proteins. To assure that the results from the SucC/SucD based assay and the 
HPLC assay are comparable the control described here was done. Turnover of (A) PnB_KS-AT2 (substrate 
malonyl-CoA) and (B) PnC_KS-AT (substrates used were ethylmalonyl- and butylmalonyl-CoA). 500 nM 
KS-AT and 400 µM cognate ACP were mixed with 600 µM substrate in 200 mM NaH2PO4, pH 7.2 (same 
protein concentrations in SucC/SucD based assay). The reaction was stopped by adding formic acid and 
samples were analyzed using HPLC. With the linear slope the turnover was calculated. The kcat of 
PnB_KS-AT2 with malonyl-CoA was 49.3 per minute and for PnC_KS-AT with ethylmalonyl-CoA 3.4 per 
minute, with butylmalonyl-CoA 0.31 per minute. With the SucC/SucD based assay a kcat of 74 
(PnB_KS-AT2), 4 (PnC_KS-AT with ethylmalonyl-CoA) and 0.6 (PnC_KS-AT with butylmalonyl-CoA) was 
measured. The determined turnover rates are similar which assures that the measured kinetics displayed 






Figure S11: Sequence alignment of AT domains from Pn PKS. Indicated are three extender unit 
specificity conferring motifs. The canonical GHS can be found in all malonyl-CoA specific Pn_AT domains 
(amino acid position 92-96), while PnC shows a GSS. Malonyl-CoA specific AT domains contain the highly 
conserved HAFH motif, methylmalonyl-CoA specific domains most commonly use the YASH motif. 
Ethylmalonyl-CoA specific AT domains have a less well conserved motif at this position, generally XAGH, 
with X being F, T, V or H 5. A motif close to this, IAGH is found in the loading AT domain from PnA. PnC 





Scheme S1: Steady state kinetic assay, relying on purified proteins. KS-AT didomains and standalone 
ACPs are used. Upon covalent binding of the acyl-residue to the AT, CoA-SH is released. With no ACP 
acceptor available, the acyl-residue is subsequently hydrolyzed by nucleophilic attack of water and the AT 
can bind a new acyl-residue. If holo-ACP is available, the acyl-residue is transferred and the AT can bind a 
new acyl-residue. Free CoA-SH is converted to succinyl-CoA by E. coli SucC/SucD. In this reaction ADP is 
produced, which can be used by pyruvate kinase/lactic dehydrogenase (PK/LDH) under NADH 




Table S1: phosphopantetheinyl coverage, selfacylation and transacylation of Pn_ACPs.  
 PnB_ACP1 PnB_ACP2 PnC_ACP PnD_ACP 
holo-ACP 26% 75% 96% 66% 
Selfacylation of ACP (%) 
M-ACP (2) 0 6.4 8.3 0 
MM-ACP (3a) 30 5.7 0 12.5 
EM-ACP (3b) 0 0 0 0 
BM-ACP (3c) 0 0 0 0 
3MBM-ACP (3d) 9.1 0 0 3.5 
HM-ACP (3e) 0 0 0 0 
BenzM-ACP (3f) 0 0 0 0 
Transacylation of ACP (%) 
M-ACP (2) 100 63.8 55.9 19.1 
MM-ACP (3a) 35.8 9.3 78.8 6.6 
EM-ACP (3b) 0 0 62 0 
BM-ACP (3c) 0 0 68.8 0 
3MBM-ACP (3d) 9.5 0 60.4 3 
HM-ACP (3e) 0 0 16.3 0 
BenzM-ACP (3f) 0 0 0 0 
 
Extent of phosphopantetheinlyation of Pn_ACP purified from E. coli BAP1. Acyl-ACP buildup upon 2 h 
incubation of 100 µM holo-ACP with 300 µM extender unit at 25°C (“selfacylation”) and acyl-ACP buildup 
upon 2 h incubation of 5 µM KS-AT, 300 µM CoA thioester, 100 µM ACP at 25°C. The percentage of apo-
, holo- and acyl-ACP was determined by mass spectrometric measurements. Substrates used were 
malonyl- (2), methylmalonyl- (3a), ethylmalonyl- (3b), butylmalonyl-CoA (3c) 3-methylbutylmalonyl- (3c), 
hexylmalonyl- (3e) and benzylmalonyl-CoA (3f).   
Malonyl-, methylmalonyl- and 3-methylmalonyl-ACP can be detected without the presence of an AT 
domain. This is likely due to transesterification of the acyl-residue from CoA to the thiolgroup of the ACP.  
In case of malonyl- and methylmalonyl-CoA this is also partly due to sfp mediated loading of the ACP during 
expression in E. coli BAP1. Subtracting already acylated ACPs (“selfacylation”) from the transacylated ACP 
produced by the AT-mediated transacylation shows that only malonyl-CoA 2 is transferred in the case of 
PnB_AT1, PnB_AT2 and PnD_AT and that all substrates (BenzM-ACP under detection limit) are transferred 




Table S2: List of polyketide masses (m/z) from the competition assays. 
 
 
Both, m/z calculated and detected are given together with the retention time. 4 corresponds to the 
tetraketide, 5 to the pentaketide and 6 to the hexaketide, b indicates ethyl-, a methyl-, c butyl-, d 




Table S3: full table of app. KM and app. kcat values for hydrolysis and transacylation by PnB_KS-AT1, 
PnB_KS-AT2, PnC_KS-AT and PnD_KS-AT. 
 Hydrolysis 













KM [µM] kcat [min
-1] kcat/ 
KM 




2 4.3±0.8 4±0.15 0.9 5.2±0.8 3±0.14 0.6 53±41 0.6±0.15 0.01 11.5±3.3 3±0.2 0.26 
3a -[a] - - - - - 73±33 1.4±0.3 0.02 - - - 
3b - - - - - - 6±1.8 0.9±0.06 0.15 - - - 
3c - - - - - - 6.2±1.4 0.7±0.04  0.11 - - - 
3d - - - - - - 20±6.7 0.8±0.08 0.04 - - - 
3e - - - - - - 19±15.5 0.4±0.08 0.02 - - - 
3f - - - - - - - - - - - - 
 Transacylation 













KM [µM] kcat [min
-1] kcat/ 
KM 




2 27±2.6 140±4.3 5.2 16±1.7 74±2 4.6 n.d[b] 0.04±0.002 - 44±7.2 28±1.8 0.64 
3a - - - - - - n.d n.d - - - - 
3b - - - - - - n.d 4±0.1 - - - - 
3c - - - - - - n.d 0.6±0.03 - - - - 
3d - - - - - - n.d 0.3±0.07 - - - - 
3e - - - - - - n.d 0.05±0.001 - - - - 
3f - - - - - - - - - - - - 




Table S4: Calculated and detected masses of holo-, apo-, and acyl-ACP.  
  PnB_ACP1 PnB_ACP2 PnC_ACP PnD_ACP 
holo-ACP calculated 12983.32 12980.41 12222.47 14046.58 
 found 12982.01 12979.0 12221.00 14045.00 
apo-ACP calculated 12643.23 12640.32 11882.38 13706.50 
 found 12642.00 12639.00 11863.00 13705.00 
M-ACP (2) calculated 13069.32 13066.41 12308.47 14132.58 
 found 13068.00 13065.00 12307.00 14131.00 
MM-ACP (3a) calculated 13083.33 13080.43 12322.48 14146.60 
 found 13082.00 13079.00 12321.00 14146.00 
EM-ACP (3b) calculated 13097.35 13094.44 12336.50 14160.61 
 found - - 12335.00 - 
BM-ACP (3c) calculated 13125.38 13122.47 12364.53 14188.64 
 found - - 12364.00 - 
3MBM-ACP (3d) calculated 13139.40 13136.49 12378.55 14202.66 
 found 13139.00 - 12378.00 - 
HM-ACP (3e) calculated 13153.41 13150.50 12392.56 14216.67 
 found - - 12391.00 - 
BenzM-ACP (3f) calculated 13159.37 13156.46 12398.52 14222.63 
 found - - 12399.00 - 
 
Given are the masses for PnB_ACP1, PnB_ACP2, PnC_ACP and PnD_ACP for the substrates 
malonyl-CoA 2 (M-ACP), methylmalonyl-CoA 3a (MM-ACP), ethylmalonyl-CoA 3b (EM-ACP), 
butylmalonyl-CoA 3c (BM-ACP), 3-methylbutylmalonyl-CoA 3d (3MBM-ACP), hexylmalonyl-CoA 3e 
(HM-ACP) and benzylmalonyl-CoA 3f (BenzM-ACP) 
 
Experimental section 
Phoslactomycin PKS in vitro assays. The production of phoslactomycin polyketide 
derivatives was initiated using PnAV4 and CHC-CoA (1), or PnB and (2Z)-
cyclohexanepropenyl-SNAC (7). The assay was run at a volume of 50 µL and contained 
the PKS proteins at 9 µM concentration, Npt at 3.5 µM and all substrates at 1 mM 
concentration (in the case of strategy 3 competition assays, the substrate concentration 
of α-substituted acyl-CoA derivatives was reduced to 0.5 mM to prevent inhibition by high 
substrate concentrations). The assays additionally contained 5 mM NADPH, 0.1 mM 
CoA, 5 mM MgCl2 and 100 mM NaH2PO4, pH 7.2. The assays were prepared on ice and 
10 µL sample was mixed with 1:1 MeOH and stored at -80°C as the negative sample. 
The assay was run at 25°C overnight, stopped with 1:1 MeOH and stored at -80 °C until 
analysis. Epimerase, to yield in the production of (2S)-acyl-malonyl-CoA derivatives, was 
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added but did not have an impact on product spectrum and was therefore left out. UPLC-
high resolution MS analysis was carried out using an Agilent 6550 iFunnel Q-TOF LC-MS 
system equipped with an electrospray ionization source set to positive ionization mode. 
The analyte was separated on a RP-18 column (50 mm x 2.1 mm, particle size 1.7 µm, 
Kinetex EVO C18, Phenomenex) using a mobile phase system comprised 0.1% formic 
acid in water (Solvent A) and acetonitrile (Solvent B). Chromatographic separation was 
carried out using the following gradient condition at a flow rate of 250 µL/min: 0 min 5% 
B; 1 min 5% B, 6 min 95% B; 6.5 min 95% B; 7 min 5% B. The column oven was set to 
40°C and auto sampler was maintained at 8°C. Standard injection volume was 10 µL. 
Capillary voltage was set at 3.5 kV and nitrogen gas was used as nebulizing (20 psig), 
drying (13 L/min, 225°C) and sheath gas (12 L/min, 40°C). MS data were acquired with a 
scan range of 50-1200 m/z.  LC-MS data were analyzed using MassHunter Qualitative 
Analysis software (Agilent). 
 
Acyltransferase steady state kinetic assay. The assay buffer (200 mM Tris, glycerol 
5%v/v, 20 mM MgCl2, pH 7.4) was used to set up all other solutions for this assay. Four 
master mixes (MM1 to MM4) in 4x concentration were prepared. For MM1 containing the 
KS-AT proteins (KS-AT or KS-ATS->A mutants), the enzymes were adjusted to 2 µM (for 
transacylation) or to 4 µM (for hydrolysis) with assay buffer additionally containing 1 mM 
DTT and 0.1 mg/mL BSA. For MM2 highly pure and concentrated ACP were adjusted to 
1600 µM concentration with the assay buffer. Substrate acyl-CoA containing MM3 was 
prepared with the assay buffer in varying substrate concentrations ranging from (4x 
concentration indicated here) 1 µM to 1 mM. MM4 contained 1.6 mM NADH, 20 mM ATP, 
30 mM succinate, 10 mM phosphoenolpyruvate (stock solutions should be resuspended 
in assay buffer, or Tris 200 mM, pH 7.4). First, these compounds were mixed and assay 
buffer was added, leaving volume for Pyruvate Kinase/Lactic Dehydrogenase (PK/LDH), 
SucC and SucD. After mixing of the compounds, the enzymes were added to MM4 like 
following: 0.06 mM SucC, 0.06 mM SucD and 20% v/v of PK/LDH (Sigma-Aldrich) (40 µL 
PK/LDH for 200 µL MM4). To measure transacylation 25 µL MM3, 25 µL MM4, 25 µL 
MM2 were mixed and incubated 30 °C for one minute. The reaction was started using 
25 µL MM1. To measure hydrolysis 25 µL MM3, 25 µL MM4, 25 µL assay buffer were 
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mixed, incubated at 30 °C for one minute. The reaction was started with 25 µL MM1. In 
both cases after starting the reaction, the mixture was immediately transferred into a 1 cm 
quartz cuvette, preheated to 30 °C and the absorption was monitored at 340 nm with a 
Cary 60 UV vis (Agilent technologies). The reactions were measured in three to four 
technical replicates. Simultaneous to the transacylation/hydrolysis reaction a negative 
control was measured. For transacylation, MM1 was replaced by assay buffer (MM2 
caused the highest background activity), for hydrolysis MM3 was replaced by assay 
buffer. For the transacylation reaction the linear slope during the first minute (seconds 30-
60) was used for measurement, for the hydrolysis the linear slope during the first two 
minutes. The slope of the negative control was subtracted of the slopes measured for the 
reactions. Prior to measuring the single kinetics of each KS-AT for each substrate, the 
KS-AT concentration was halved and the velocity was calculated, to assure 
measurements where the assay is not rate limiting. 
 
HPLC analysis of ACP loading by KS-AT. Loading of holo-ACPs was initiated by adding 
KS-AT with a final concentration of 5 µM to the cognate ACP 100 µM and a single 
acyl-CoA ester 300 µM. Phosphopantetheinylation of apo-ACPs by the 
4’-phosphopantetheinyl transferase was initiated by adding Npt with a final concentration 
of 1 µM to a mix containing 100 µM ACP, 5 mM MgCl2, 200 mM NaH2PO4 and 1.5 µM 
CoA. The reactions were run at 25 °C and stopped by addition of formic acid and injected 
onto a Discovery BIO Widepore C5 HPLC column. Solvents contained 0.1% TFA. Solvent 
A was distilled water and Solvent B was acetonitrile. Chromatographic separation was 
carried out using following gradient condition at a flow rate of 1.5 mL/min: 0 min 5% B; 
3 min 35% B; 28 min 50% B; 29 min 95% B; 30 min 5% B. Colum temperature was 40 °C. 
ACP elution was monitored at 220 nm wavelength. 
 
HPLC kinetic analysis of PnC_KS-AT. The assay contained final concentrations of 
100 µM PnC holo-ACP, 5 µM PnC KS-AT, 300 µM acyl-CoA thioester and 50 µM 
NaH2PO4, pH 7.2. Reactions were run at 25°C and stopped by addition of formic acid and 
injected onto a Discovery BIO Widepore C5 HPLC column. Solvents used were distilled 
water (Solvent A) and acetonitrile (Solvent B), both containing 0.1% TFA. 
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Chromatographic separation was carried out using following gradient condition at a flow 
rate of 1.5 mL/min: 0 min 5% B; 3 min 35% B; 28 min 50% B (for butyl-, 3-methylbutyl- and 
hexylmalonyl-CoA)/ 3 min 36,5% B; 28 min 37,8% B (for malonyl-CoA)/ 3 min 35% B; 
28 min 43% B (for ethylmalonyl-CoA). Followed by 29 min 95% B; 30 min 5% B. Colum 
temperature was 40°C. ACP elution was monitored at 220 nm wavelength. Time points 
were measured in technical triplicates. The linear increase during the first minutes was 
used to calculate the transacylation rate.  
 
Mass spectrometric measurements of standalone ACPs. Loading of holo- and 
apo-ACPs by KS-AT and Npt was done as described above. All reactions were run at 
25°C for 2 h and placed on 4°C until analysis by mass spectrometry. 2 µL of the buffered 
protein solutions were desalted online using a Waters ACQUITY H-Class HPLC-system 
equipped with a MassPrep column (Waters). Desalted proteins were eluted into the ESI 
source of a Synapt G2Si mass spectrometer (Waters) by the following gradient of buffer 
A (water with 0.05% formic acid) and buffer B (acetonitrile with 0.045% formic acid) at a 
column temperature of 60°C and a flow rate of 0.1 mL/min: Isocratic elution with 5% A for 
two minutes, followed by a linear gradient to 95% B within 8 minutes and holding 95% B 
for additional 4 minutes. Positive ions within the mass range of 500-5000 m/z were 
detected. Glu-Fibrinopeptide B was measured every 45 s for automatic mass drift 
correction. Averaged spectra were deconvoluted after baseline subtraction and 
eventually smoothing using MassLynx instrument software with MaxEnt1 extension. 
 
Synthesis of acyl-CoAs. Acyl-CoA synthesis was done like previously described. 
CHC-CoA was synthesized by chemical CDI coupling of the free acid, analogous as 
previously explained 6. 
 
Construction of plasmids used in this study. The coding sequence for the 
phoslactomycin polyketide synthase genes from Streptomyces platensis was synthesized 
and codon optimized by the Joint Genome Institute. Inserts were amplified by PCR. 
Oligonucleotides with overhangs for the restriction enzymes NdeI (CATATG) and HindIII 
(AAGCTT) were used and the agarose gel purified fragments were ligated into the cloning 
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vector pJET1.2. From there the insert was cut out with NdeI and HindIII and inserted into 
expression vectors. SucC (Accession number WP_113400154) and SucD (Accession 
number WP_096861694) coding sequence was amplified by colony-PCR from E.coli 
strain Top10 and cloned following the procedure above. Npt coding sequence was codon 
optimized for E.coli and synthesized.  All cloning was done using the E.coli strain Top10. 
Catalytic knock out mutants were constructed using mismatching oligonucleotides, 
containing the DNA triplet for the desired amino acid. The plasmid was divided into two 
or three parts and amplified by PCR using Q5® High-Fidelity DNA polymerase. The 
purified fragments were assembled using the Gibson Assembly ® Master Mix purchased 
from New England Biolabs. 
 




pET21a(+) PnAF4 C-terminal 251.74 251.79 
pET21a(+) PnB C-terminal 354.42 401.39 
pET21a(+) PnBY3074F C-terminal 354.39 399.90 
pET21a(+) PnB-TEDEBS C-terminal 374.95 437.96 
pET21a(+) PnC C-terminal 176.81 202.08 
pET21a(+) PnC Y1367F C-terminal 176.79 200.59 
pET21a(+) PnC-TEDEBS C-terminal 198.99 238.65 
pET21a(+) PnCY1367F-TEDEBS  C-terminal 198.98 237.16 
pET21a(+) PnD C-terminal 197.11 172.40 
pET21a(+) PnD-TEDEBS C-terminal 221.18 202.10 
pET21a(+) Npt C-terminal 25.78 36.11 
pET28b(+) PnB-KSAT1 N-terminal 97.19 102.25 
pET28b(+) PnBS669A-KSAT1  N-terminal 97.17 102.25 
pET28b(+) PnB-ACP1 N-terminal 12.77 / 
pET28b(+) PnB-KSAT2 N-terminal 96.76 89.76 
pET28b(+) PnBS671A-KSAT2  N-terminal 67.74 89.76 
pET28b(+) PnB-ACP2 N-terminal 12.77 / 
pET28b(+) PnC-KSAT N-terminal 101.32 114.74 
pET28b(+) PnCS684A-KSAT  N-terminal 101.30 114.74 
pET28b(+) PnC-ACP N-terminal 12.01 / 
pET28b(+) PnD-KSAT N-terminal 100.57 85.75 
pET28b(+) PnDS681A-KSAT N-terminal 100.55 85.75 
pET28b(+) PnD-ACP N-terminal 13.84 / 
pET28b(+) SucC N-terminal 43.56 27.18 




Protein expression and purification. Expression constructs encoding for proteins with 
an ACP domain were transformed into E.coli BAP1 or BL21 (DE3) competent cells, all 
other constructs were transformed into E.coli BL21 (DE3) and supplemented with the 
respective antibiotics. Overnight cultures of 10 mL LB were inoculated with a single 
colony and used for inoculation of 1 L Terrific Broth medium. Cells were grown at 37 °C 
until they reached an OD600 of 1, induced with 100 µM isopropyl-β-
D-thiogalactopyranoside and PKS proteins were expressed at 16°C shaking at 90 rpm for 
approximately 15 h. Cells were harvested, immediately used for purification or stored at -
20°C. The other proteins were expressed at 18°C. SucC and SucD were expressed at 
23°C.  
 
Protein Nickel NTA-purification. Cell pellets were resuspended in Buffer A (500 mM 
NaCl, 50 mM NaH2PO4, 10% v/v glycerol, pH 7.5) and lysed by sonication, centrifuged at 
42.000 g, 4 °C for 45 min and the supernatant was mixed with 3.5 mL Protino® Ni-NTA 
Agarose purchased from Macherey Nagel and incubated for 2 h on ice with slow shaking. 
The beads solution was transferred into Protino® Columns 14 mL, washed with 50 mL 
Buffer A. Following the beads were washed with 20 mL washing buffer (25 mM Imidazole, 
500 mM NaCl, 50 mM NaH2PO4, 10% v/v glycerol, pH 7.5). Proteins were eluted with 
8 mL Buffer B (500 mM Imidazole, 500 mM NaCl, 50 mM NaH2PO4, 10% v/v glycerol, 
pH 7.5). SucC, SucD, Npt and all standalone ACP proteins were further purified by size 
exclusion using HiLoad 16/600 Superdex 200 pg column (300 mM NaCl, 25 mM 
NaH2PO4, pH 7.5). All other proteins were subjected to anion exchange. Protein 
concentration was determined by UV-vis measurements at 280 nm, in the case of ACPs 
concentration was determined by Bradford assay. 
 
Anion exchange. The eluate from the Nickel beads purification was diluted to 120 mL 
with Anion A (50 mM NaH2PO4, pH 7.5) and loaded onto a 5 mL HiTrap Q HP anion 
exchange 5 mL chromatography column, purchased from GE Healthcare Life Sciences, 
with a flow of 3 mL/min. A gradient to 100% Anion B (50 mM NaH2PO4, 500 mM NaCl 
pH 7.5) with a flow of 4 mL/min in 30 min was run and protein containing fractions were 
collected and concentrated using Amicon® Ultra Centrifugal Filters, purchased from 
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Merck Millipore. Proteins were used immediately for assays or stored with 30% v/v 
glycerol in -80 C after shock freezing in liquid nitrogen.  
 
Synthesis of (2Z)-cylcohexanepropenyl-SNAC 
General Information. All non-aqueous reactions were carried out using flame-dried 
glassware under argon atmosphere. All solvents were distilled by rotary evaporation. 
Solvents for non-aqueous reactions were dried as follows prior to use: Tetrahydrofuran 
(THF) was dried with potassium hydroxide and subsequently distilled from Solvona®. 
Dichloromethane and triethylamine were distilled from calcium hydride. 
N-acetylcysteamin (HSNAC) was synthesised according to literature 7. All other 
commercially obtained reagents were used as received. Reactions were monitored by 
thin layer chromatography (TLC) using Merck Silica Gel 60 F254-plates and visualised by 
fluorescence quenching under UV-light. In addition, TLC-plates were stained using a 
potassium permanganate stain. Chromatographic purification of products was performed 
on Merck Silica Gel 60 (230-400 mesh) unless otherwise noted using a forced flow of 
eluents. Concentration in vacuo was performed by rotary evaporation at 40 °C and 
appropriate pressure and by exposing to fine vacuum at room temperature if necessary. 
NMR spectra were recorded on a Bruker AV 300 MHz, AV III 500 MHz, AV III HD 500 
MHz spectrometer at room temperature. Chemical shifts are reported in ppm with the 
solvent resonance as internal standard. Data are reported as follows: s = singlet, d = 
doublet, t = triplet, q = quartet, quint = quintet, m = multiplet. Mass spectra were recorded 
by the mass service department of the Philipps-Universität Marburg. HR-ESI mass 
spectra were acquired with an LTQ-FT mass spectrometer (Thermo Fischer Scientific). 
The resolution was set to 100 000. IR spectra were recorded on a Bruker IFS 200 
spectrometer. The absorption bands are given in wave numbers (cm-1), intensities are 
reported as follows: s = strong, m = medium, w = weak, br = broad band. Melting points 
were determined on a Mettler Toledo MP70 using one end closed capillary tubes. Optical 










To a solution of Still-Gennari-reagent (0.64 mL, 3.03 mmol, 1.20 eq.) and 18-crown-6 
(0.77 g, 2.90 mmol, 1.15 eq.) in tetrahydrofuran (15 mL) at 0 °C under an argon 
atmosphere was added a solution of potassium bis(trimethylsilyl)amide (0.5 m in toluene, 
5.80 mL, 2.90 mmol, 1.15 eq.) dropwise. After 30 min the solution was cooled to -78 °C 
and aldehyde 10 (0.30 mL, 2.52 mmol, 1.00 eq.) was added dropwise. The solution was 
stirred 1 h at -78 °C and afterwards reaching room temperature overnight. A sat. solution 
of ammonium chloride and diethyl ether were added, the layers separated and the 
aqueous was extracted with diethyl ether (3x). The combined extracts were dried 
(magnesium sulphate), the volatiles removed in vacuo and the residue was purified by 
flash chromatography (silica gel, pentane/diethyl ether 50:1) to give (Z)-ester 9 (0.37 g, 
2.20 mmol, 87%) as colourless liquid. TLC: Rf = 0.40 (pent/diethyl ether 50:1); 
1H-NMR (500 MHz, CDCl3): δ = 6.03 (dd, J = 11.5, 10.0 Hz, 1H, CyCH=CH), 5.66 (dd, 
J = 11.5, 1.0 Hz, 1H, CyCH=CH), 3.70 (s, 3H, OCH3), 3.34-3.25 (m, 1H, Cy-CH), 
1.74-1.64 (m, 5H, Cy-CH2), 1.40-1.30 (m, 2H, Cy-CH2), 1.23-1.13 (m, 1H, Cy-CH2), 
1.12-1.03 (m, 2H, Cy-CH2) ppm; 13C-NMR (125 MHz, CDCl3): δ = 166.8 (CO2Me), 156.1 
(CyCH=), 117.1 (CyCH=CH), 51.0 (OCH3), 37.3 (Cy-CH), 32.3 (2xCy-CH2), 
25.9 (Cy-CH2), 25.4 (2xCy-CH2) ppm; HRMS (ESI+): m/z calcd. for C9H13O [M+Na]+ 
191.1043, found 191.1042; υmax(film): 2965 (w), 2926 (s), 2854 (w), 2358 (m), 2035 (m), 









To a solution of (Z)-ester 9 (104 mg, 0.62 mmol, 1.00 eq.) in a 5:1:1 mixture of 
tetrahydrofuran/water/methanol (7 mL) at room temperature was added lithium hydroxide 
monohydrate (259 mg, 6.18 mmol, 10.0 eq.) and the mixture was stirred overnight. After 
addition of water the pH-value was adjusted (pH=3) with hydrochloric acid (1 m), the 
mixture extracted with diethyl ether (3x) and the combined extracts were dried 
(magnesium sulphate). The volatiles were removed in vacuo and the residue purified by 
flash chromatography (silica gel, pentane/ethyl acetate 3:1) to give (Z)-acid 8 (80 mg, 
0.52 mmol, 84%) as white solid. TLC: Rf = 0.55 (pent/ethyl acetate 1:1); 
1H-NMR (500 MHz, CDCl3): δ = 6.15 (dd, J = 11.3, 10.2 Hz, 1H, Cy-CH=), 5.67 (d, 
J = 11.3 Hz, 1H, Cy-CH=CH), 3.33-3.26 (m, 1H, Cy-CH), 1.73-1.64 (m, 5H, Cy-CH2), 
1.42-1.30 (m, 2H, Cy-CH2), 1.25-1.06 (m, 3H, Cy-CH2) ppm (CO2H was not detectable 
due to fast exchange with the solvent); 13C-NMR (125 MHz, CDCl3): δ = 170.0 (CO2H), 
158.1 (Cy-CH=), 116.6 (Cy-CH=CH), 37.4 (Cy-CH), 32.3 (2xCy-CH2), 25.9 (Cy-CH2), 
25.4 (2xCy-CH2) ppm (CO2H was not detectable due to low Cq-intensity); HRMS (ESI−): 
m/z calcd. for C9H13O2 [M]− 153.0921, found 153.0921; υmax(film): 2926 (s), 2852 (w), 
2734 (w), 2575 (w), 1694 (s), 1638 (w), 1439 (m), 1351 (w), 1290 (w), 1270 (w), 1242 
(m), 1215 (w), 1135 (w), 1029 (w), 965 (w), 931 (w), 892 (w), 827 (w), 798 (w), 729 (w), 









To a solution of acid 8 (20 mg, 0.13 mmol, 1.00 eq.) in dichloromethane (2 mL) at 0 °C 
under an atmosphere of argon were added N-acetylcysteamine (62 mg, 0.52 mmol, 
4.00 eq.), 2,2-dimethylaminopyridine (cat.) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (40 mg, 0.21 mmol, 1.60 eq.) 
successively. The mixture was stirred reaching room temperature over night after which 
water was added. The aqueous layer was extracted with dichloromethane (3x), the 
combined extracts were dried (magnesium sulphate) and the volatiles removed in vacuo. 
The residue was purified by flash chromatography (silica gel, pentane/ethyl acetate 1:1) 
to give SNAC-ester 7 (30 mg, 0.11mmol, 82%) as pale yellow oil. TLC: 
Rf = 0.17 (pent/ethyl acetate 1:1); 1H-NMR (500 MHz, CDCl3): δ = 5.97 (dd, J = 11.3, 
0.67 Hz, 1H, Cy-CH=), 5.87 (dd, J = 11.3, 9.7  Hz, 1H, Cy-CH=CH), 5.83 (bs, 1H, NH), 
3.47 (q, J = 6.2 Hz NCH2), 3.23-3.15 (m, 1H, Cy-CH), 3.08 (t, J = 6.2 Hz 2H, SCH2) 1.97 
(s, 3H, CH3), 1.75-1.64 (m, 5H, Cy-CH2), 1.37-1.29 (m, 2H, Cy-CH2), 1.22-1.06 (m, 3H, 
Cy-CH2) ppm; 13C-NMR (125 MHz, CDCl3): δ = 189.8 (OCS), 153.1 (Cy-CH=), 
124.0 (Cy-CH=CH), 39.8 (NCH2), 38.4 (SCH2), 32.2 (2xCy-CH2), 28.6 (Cy-CH), 25.8 
(Cy-CH2), 25.4 (2xCy-CH2) ppm; HRMS (ESI+): m/z calcd. for C13H21NO2SNa [M+Na]+ 
278.1185, found 278.1187; υmax(film): 3283 (w), 3080 (w), 2924 (s), 2850 (w), 1672 (w), 
1653 (s), 1623 (w), 1550 (m), 1446 (w), 1408 (w), 1373 (w), 1289 (w), 1262 (w), 1197 (w), 































DNA sequences of the constructs used for this study. The in this study used KS-AT 
and ACP constructs are indicated by caption in the following DNA sequences. Marked in 
bold is the module linker sequence that is replaced with DEBS_TE in the cases of PnB, 
PnC and PnD for PnB-TEDEBS, PnC-TEDEBS and PnD-TEDEBS constructs. 
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Abstract  
Polyketide synthases (PKS) join basic building blocks in an assembly line fashion, which 
leads to the production of structural highly diverse polyketides. Most PKS biosynthetic 
gene clusters contain a gene encoding for a type II thioesterase (TEII). TEIIs restore the 
productivity of PKS by removing aberrant modifications on the acyl-carrier proteins (ACP), 
which cause a blockage of the assembly line. This function is commonly referred to as an 
editing function. Here, we investigated the function of PnG, the TEII from the 
phoslactomycin (Pn PKS) gene cluster, on its cognate modular type I PKS in vitro. 
Detailed biochemical analysis revealed a strong preference of PnG towards alkyl-ACPs 
over (alkyl)malonyl-ACPs, supporting the editing role of this TEII. In phoslactomycin 
pentaketide assays, we showed the PnG dependent increase in production of native as 
well as non-native polyketides. We additionally demonstrate that PnG is able to 
functionally replace the terminal TEI of the chimeric Pn PKS system in vitro by releasing 
terminal polyketides from the assembly line. Furthermore, we provide insights in the origin 









Polyketide synthases (PKS) are multifunctional enzyme complexes that biosynthesize 
natural products with great structural complexity and diverse bioactivity. The structural 
backbone of these compounds is synthesized through condensation of simple 
(alkyl)malonyl-CoA precursors via the successive function of discrete PKS domains in an 
assembly line fashion. The final polyketide backbone is usually released by a covalently 
bound terminal thioesterase domain. Besides the terminal thioesterase, most PKS, but 
also nonribosomal peptide synthethase (NRPS) gene clusters, encode a type II 
thioesterase (TEII). The majority of the information on TEIIs was gained by gene 
disruption and replacement strategies, which showed effects from complete loss of 
product formation, over reduced amounts, to no change in natural product titers 1-9. 
Co-expression of TEIIs was successfully used to increase the yield of natural product 
production 10-12, while strong overexpression resulted in reduced product amounts, 
indicating a tradeoff between removing blocking modifications and productive 
intermediates 6, 13.  
It was suggested that TEIIs display an editing function, whereby aberrant 
precursors that block the assembly line are removed, to allow continued synthesis 4, 14. 
Other reported functions of TEIIs are the release of the final product 12, 15, 16, the control 
of the pool size of CoA-thioester precursors 1, the control of starter units 17, 18, and the 
unspecific release of short acyl-residues and late stage intermediates 19. The blockage of 
PKS assembly lines has been proposed to originate from a slow, unproductive 
decarboxylation of (alkyl)malonyl extender units bounds to their cognate acyl-carrier 
protein (ACP) 20-24. Another potential source of unreactive alkyl-ACPs in the PKS 
assembly line is the conversion of apo-ACPs into their active holo forms through the 
attachment of the phosphopantetheine prosthetic (4’PP) group to the ACP by specific 
transferases 10, 25, 26. The role of TEIIs in editing (i.e. clearing) unreactive alkyl-units is 
supported by data that shows that these enzymes prefer decarboxylated (i.e. alkyl-) over 
carboxylated residues, and ACP tethered over CoA/N-acetylcysteamine tethered 
substrates 27. 
Two models have been proposed for the general editing function of TEIIs. In the 
high specificity model, the TEII efficiently removes aberrant acyl units. In the low 
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specificity model, the TEII removes both aberrant and correct units with low efficiencies 20, 
27. Since correct substrates will be efficiently processed by the PKS assembly line, they 
are protected from the TEII, while incorrect, aberrant units will lead to assembly line 
stalling and become exposed to the TEII, followed by removal. 
Only a few TEIIs have been studied in vitro together with the cognate NRPS or 
PKS system. YbtT, the TEII from yersiniabactin hybrid NRPS/PKS did not have an effect 
on the in vitro system, when only the native substrates were present. Later it was found 
to remove non-canonical precursors that blocked the synthesis in vitro, therefore restoring 
full biosynthetic activity 13, 28.  In the reconstituted type II PKS of enterocin and 
tetracenomycin, the TEII EncL and ZhuC, respectively, were shown to impact starter unit 
selection 17, 18. Besides selection of starter units, regio-specific selection and incorporation 
of extender units must be assured. This becomes especially apparent in modular type I 
PKS, that incorporate multiple extender units, such as the phoslactomycin (Pn) PKS 
which uses cyclohexanecarboxyl-CoA as starter unit and malonyl- and ethylmalonyl-CoA 
as extender units. Here we investigated the role of PnG, the TEII from the phoslactomycin 
biosynthetic gene cluster 29, on the production of phoslactomycin derivatives using a 
recently established in vitro system 30. We biochemically characterized PnG, and provide 
data that support both decarboxylation during polyketide assembly and miss-loading 
during protein production as the origin of the aberrant units, blocking the assembly line. 
PnG exhibits a broad substrate tolerance and is capable of releasing final polyketides, 
replacing the function of the terminal thioesterase while at the same time, increasing the 





Results and discussion 
Heterologous expression and purification of PnG and Pn PKS enzymes. 
6xHis-tagged PnG protein was purified to homogeneity by Ni-NTA purification, followed 
by size exclusion chromatography (Figure S1). PnG eluted as a monomeric protein with 
34.4 kDa size (calculated 30.17 kDa), which is in line with the general assumption that 
TEIIs are functional as monomers 27, 31, 32. Active site knockout PnG S93G showed the 
same elution patterns as the wild type. Enzymes of the Pn PKS were purified as 
previously described 30. 
 
PnG hydrolyses decarboxylated acyl-ACPs. 
First, we determined the kinetic parameters of PnG. For this, we used two different ACPs 
from the native phoslactomycin PKS (Pn PKS), ACPLD (from the loading domain of PnA) 
and ACP2 (from the first module of PnB) as substrate templates (Table 1, Figure S2). We 
loaded these ACPs with different acyl-residues using Npt, the promiscuous 
phosphopantetheinyl-transferase from Streptomyces platensis 30. PnG was equally active 
with both ACPs, which is in line with the observation that TEIIs generally show low 
specificity towards the carrier protein 2, 6, 13.  
 
Table 1: Reaction parameters for PnG hydrolytic activity with various acyl-residues bound to ACPLD and 
ACP2 with the standard error of the mean.  
Substrate kcat [min-1] KM [µM] kcat/KM [M-1s-1] 
decarboxylated substrates 
Acetyl-ACPLD 618 ± 45 47 ± 17 2.2x105 ± 8x104 
Butyl- ACPLD 493 ± 38 23 ± 9 3.6x105 ± 1.4x105 
Acetyl-ACP2 965 ± 56 27 ± 7 6x105 ± 1.6x105 
Propionyl-ACP2 2050 ± 358 139 ± 57 2.5x105 ± 1.1x105 
Butyl-ACP2 353 ± 39 23 ± 12 2.6x105 ± 1.4x105 
carboxylated substrates 
Malonyl- ACPLD 259 ± 31 293 ± 109 1.5x104 ± 5.8x103 
Ethylmalonyl- ACPLD 10 ± 0.8 501 ± 113 3.3x102 ± 8x101 
Malonyl-ACP2 77 ± 13 164 ± 99 7.8x103 ± 4.9x103 
Methylmalonyl-ACP2 20 ± 5 369 ± 196 9x102 ± 5.3x102 




Our kinetic analysis showed distinct differences in the hydrolytic activity of PnG 
between the two substrate classes tested (Table 1). PnG hydrolyzes all tested alkyl-ACPs 
representing the decarboxylated substrates (acetyl-, propionyl- and butyl-ACP) with 
similar specificity constants ranging from 2.2x105 to 6x105 M-1 s-1, indicating no 
preference for chain length as for instance observed for RedJ, the TEII in the prodiginine 
biosynthesis cluster 31. When we tested carboxylated (alkyl)malonyl-ACP substrates, 
however, we observed a 45 to 50-fold preference for malonyl- over ethylmalonyl-ACP 
indicating that PnG is able to distinguish between shorter and longer carboxylated 
substrates, which might protect ethylmalonyl-ACP from futile hydrolysis.  
When comparing hydrolytic activity between (alkyl)malonyl-ACP substrates and 
their decarboxylated analogs, we observed that PnG displays a strong discrimination 
towards the latter. PnG preferred acetyl-ACP over malonyl-ACP with a 14 to 75 fold 
increased specificity constant. In the case of propionyl-/methylmalonyl-ACP and 
butyl-/ethylmalonyl-ACP we determined a 150-fold and 1000- to 1500-fold increase in 
specificity, respectively. Preferences for decarboxylated over carboxylated substrates 
were also reported with other TEII 5, 13, 27, 31, however not as pronounced as in the case 
of PnG. Our kinetic data shows that this preference for the decarboxylated substrate is 
caused by both high KM values, as well as low turnover rates. Altogether, these results 
suggest that the hydrolysis of carboxylated substrates from ACPs is negligible under 
physiological conditions.  
 
PnG leads to higher production of polyketides in vitro.  
To investigate if PnG, encoded in the biosynthetic gene cluster of phoslactomycin 29 has 
an effect on phoslactomycin biosynthesis, we tested the enzyme in the context of the 
recently established Pn PKS in vitro system for the production of tetra- and pentaketides 
(Scheme1) 30. In this system, polyketide biosynthesis is initiated by PnAV4 with 
cyclohexanecarboxyl-CoA and malonyl-CoA and continued by PnB using two malonyl-
CoA, yielding tetraketide (4). For production of pentaketide (5), another extension of 4 is 
followed through PnC. While PnC incorporates ethylmalonyl-CoA (3b) in the native 
context (Figure S3), it was shown that its acyltransferase (AT) is promiscuous and 
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accepts different non-native extender units (3a, 3c-3e) with a preference for medium side 
chain lengths substrates 3b-3d, which leads to pentaketides 5a-5d.  
 
 
Scheme 1: Assay scheme for characterization of PnG. Tetraketide (4) or pentaketide (5) production is 
initiated by PnAV4, terminates with PnB-TEDEBS in case of 4, or with PnC-TEDEBS in case of 5. Substrates 
used are cyclohexanecarboxyl-CoA (1), malonyl-CoA (2) and in single extender unit pentaketide production 
assays one, in the case of competitive assays all five α-substituted extender units (a methyl-, b ethyl-, 
c butyl-, d 3-methylbutyl- and e hexyl-malonyl-CoA). Ethylmalonyl-CoA 3b is the native substrate of PnC, 
however 3a to 3e are incorporated into the pentaketide. 
 
In the tetraketide system, the presence of PnG increased production of 4 between four- 
and five-fold, independent of the PnG concentration (Figure 1A, Figure S4). Addition of 
PnG S93G, a catalytic knockout control, did not impact polyketide biosynthesis (Figure 
S5). To test whether the mis-loading of ACPLD might affect the assembly line we tested 
the effect of acetyl-CoA, a common metabolite, on tetraketide production. When adding 
1 mM acetyl-CoA to the tetraketide assays, production of 4 was unaffected by the 
presence or absence of PnG, which ruled out acetyl-CoA mis-loading of ACPLD as a 
significant mechanism for assembly line stalling (Figure 1A). This was further supported 
by the fact that no production of modified 4, as result of acetate starter incorporation was 
observed in presence or absence of PnG. Altogether, these experiments demonstrate a 
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Figure 1: Effect of increasing PnG concentration on polyketide production in vitro. Concentrations of PnG 
ranged between 0.1 and 2 molar equivalents of ACPs present in the assay, indicated on the x-axis. All 
values were set relative to the control without PnG. Samples were taken after 2 h and measured by mass 
spectrometry. (A) Tetraketide 4 production with the native substrates and additionally with acetyl-CoA. (B) 
Pentaketide 5a-e production with 2 and one α-substituted malonyl-CoA derivative 3a-e as extending 
substrates. (C) Pentaketide production in competitive conditions with all substrates 1, 2 and 3a-e. (D) 
Pentaketide 5a-e production in competitive conditions with pretreated Pn PKS enzymes, cleared of potential 
ACP-tethered acyl-residues. Pre-incubation with PnG assures removal of all acyl-residues. In B, C and D 
the heat map indicates the initial product distribution, set relative to the native product 5b. Residues 
indicated are: a=methyl-, b=ethyl-, c=butyl-, d=3-methlbutyl-, e=hexyl-residues. A negative control with 
PnG S93G catalytic knockout was used (Figure S5). Data points are from multiple biological (A, C, D) and 
technical (A, B, C, D) replicates. For a list of the product masses refer to Table S1. 
 
 
For the pentaketide system we supplied 1, 2 and either one α-substituted extender 
unit alone, or all five α-substituted extender units at the same time in a competitive assay 
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presence of native (2 and 3b) or non-native (3a, 3c-3e) extender units and to detect an 
effect of PnG on Pn PKS system that is challenged with multiple substrates 
simultaneously.  
In pentaketide assays, we observed incorporation of the respective extender unit 
in each case (Figure 1B-D, Figure S4). In the absence of PnG, we detected an initial 
pentaketide distribution between 5a-5e as reported before, with minor amounts of 5a and 
with 5b-d as the main products 30. Tandem mass spectrometry confirmed the structures 
of pentaketides 5a-5e (Figure S6). As for the tetraketide system, addition of PnG in the 
pentaketide system strongly increased product formation. In assays with only one single 
α-substituted extend present (Figure 1B), formation of 5a was increased 13-fold (note that 
initial amount had been close to detection limit), while 5b-d were increased around 
nine-fold. Finally, production of 5e was changed only three-fold and remained unaltered 
upon high concentrations of PnG.  
In competitive extender unit assays, containing all five α-substituted extender units 
(Figure 1C, Figure S4) we observed an increase on the production of 5a-5e, particularly 
upon low concentrations of PnG. The beneficial effect of PnG was most pronounced on 
5b, the native product, with a 14-fold increase, followed by 5c (nine-fold), 5d (seven-fold), 
5a (six-fold) and 5e (three-fold). Production of 5a was also increased several-fold 
compared to the initial concentrations that had been close to the detection limit. Overall, 
these results showed that PnG generally has a beneficial effect on tetra- and pentaketide 
production in vitro and increases of up to 14-fold more product can be observed.  
As mentioned above, TEIIs remove unwanted modifications on the reactive thiol 
group of the 4’-PP cofactor of ACPs, that block the assembly line. These modifications 
can originate from the slow, unproductive decarboxylation of (alkyl)malonyl-ACPs or the 
mis-loading of ACPs by promiscuous phosphopantetheinyl-transferases. To test if 
mis-loading of ACPs during protein production in E. coli BAP1 plays a role, we pre-treated 
purified Pn PKS enzymes with Npt, the native transferase from S. platensis, CoA and 
PnG to ensure complete activation and clear all acyl-residues from ACPs. By size 
exclusion chromatography PnG and Npt were removed and Npt was omitted from the 
assays to circumvent mis-loading of any residual apo-ACPs. Notably, with these 
pretreated enzymes, increase of pentaketide production was still observed (Figure 1D, 
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Figure S4). As before, low to medium concentrations of PnG showed the most prominent 
effect. Production of 5a, 5b, 5c and 5d, was increased between three- and five-fold, while 
the effect on 5e was negligible. Overall, these experiments suggest that the action of PnG 
is a cumulative effect of clearing mis-loaded ACPs before and during Pn biosynthesis, 
where slow, unproductive decarboxylation of (alkyl)malonyl-ACPs takes place. 
We were interested if PnG impacts all Pn PKS proteins similarly. Pn polyketide 
biosynthesis can be initiated by PnAV4 or by PnB, when providing the diketide SNAC 
substrate analog and terminated with PnB-TEDEBS (for 4) or PnC-TEDEBS (for 5) 30. 
Production of 4 and 5 when initiated with PnAV4 was increased approx. five- and 14-fold, 
respectively, upon addition of PnG (Figure 1). When bypassing PnAV4 with the diketide 
SNAC ester no beneficial effect on the production of 4 was observed, while an eight-fold 
increase can be detected for production of 5 (Figure S7A). This data indicates either a 
stronger impact of PnG on PnAV4 and PnC-TEDEBS than on PnB or an inhibition of PnG 
caused by the presence of the diketide SNAC. An inhibition of PnG would lead to a less 
pronounced effect when adding the SNAC ester to the full pentaketide 5 assembly line. 
To investigate this further, we supplied the SNAC thioester to pentaketide assays initiated 
with PnAV4 and PnB as a control and observed a decrease of PnGs production promoting 
effect (Figure S7B). This suggests that PnG binds the SNAC thioester as substrate and 
is occupied by it (due to slower turnover), showing a negative effect of the presence of 
these polyketide analogs on this TEII.  
In general, low amounts of PnG resulted in a maximum increase of product 
formation. High PnG concentrations on the other hand had a less beneficial or even 
negative impact on biosynthesis, particularly in case of non-native, long α-substituents 
(i.e. hexyl-residue of 3e). This observed negative effect could be caused by increased 
PnG catalyzed clearing of non-native (alkyl)malonyl extender units bound to the ACP or 
the corresponding CoA esters, as some TEIIs were shown to hydrolyze CoA thioesters 
at low activity 26, 27. To rule out the latter, we incubated PnG with all CoA thioester 
substrates used in this study. Even after several hours of incubation, CoA ester hydrolysis 
was below the detection limit (Figure S8). We concluded that the negative effect of 
increased PnG concentrations on the production of non-native pentaketides was caused 
by an increased hydrolysis of ACP bound (alkyl)malonyl extenders, probably due their 
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slower turnover and thus increased exposition to PnG. Notably, this effect of PnG leads 
to a shaping of the product profile in competitive pentaketide assays towards the native 
product (5b) (Figure S9) and supports the low specificity model of TEIIs, according to 
which hydrolysis of native extender units is rather inefficient and does not compete with 
chain elongation 20, 27.  
 
Release of polyketides by PnG. 
Finally, we assessed whether PnG is able to release polyketides from the assembly line. 
Therefore, we first tested the pentaketide assembly line in a competitive assay without 
the terminal thioesterase TEDEBS (PnAV4+PnB+PnC) (Figure 2, Figure S10). Without 
TEDEBS, the initial product distribution pattern was similar to assays terminating with 
TEDEBS, while the product amount was strongly reduced below 5%. This supports the 
functionality of TEDEBS in that system. Addition of PnG in low to medium concentrations 
increased product formation for all pentaketides. Production of 5a and 5e was increased 
around one order of magnitude, while formation of 5c and 5d was increased around two 
orders of magnitude and formation of the native product 5b by 200-fold. Compared to the 
system terminating with TEDEBS, final product levels reached 50% (5d), 70% (5c) and 90% 
(5b) with PnG, respectively.  
 
 
Figure 2: PnG releases pentaketides. Pentaketide production in competitive assays lacking a terminal 
thioesterase. Concentrations of PnG ranged between 0.1 and 2 molar equivalents of ACPs present in the 
assay, indicated on the x-axis. All samples were taken after 2 h incubation and analyzed by mass 
spectrometry. (A) The heat map displays the initial relative amounts of the pentaketides 5a-e in the absence 









































PnG can be observed for all pentaketides, in particular 5b-5d. (B) Heat map showing the production yield 
in percentage of assays terminating without (PnAV4, PnB, PnC) compared to assays terminating with TEDEBS 
(PnAV4, PnB, PnC-TEDEBS) with increasing PnG concentrations. Results shown for the most prominent 
products 5b, 5c and 5d. Residues indicated are: a=methyl-, b=ethyl-, c=butyl-, d=3-methlbutyl-, 
e=hexyl-residues. 
 
We then tested the hexaketide system of phoslactomycin 30 whether a similar effect 
with PnG can be observed. Unexpectedly and in contrary to what we observed in the 
pentaketide system, the detected hexaketide amount was increased two-fold in the 
absence of TEDEBS, pointing towards incapability of this terminal TE for hexaketide 
release. Addition of PnG to the system with TEDEBS resulted in five-fold, without TEDEBS in 
20-fold product increase (Figure S11). Overall this data demonstrates that PnG is capable 
of releasing products from the terminal modules of Pn polyketide systems. Furthermore, 
it shows that PnG can functionally replace the chimeric TEDEBS in the pentaketide system 
and circumvent product release limitations caused by the terminal TE due to its broad 
substrate spectrum.  
We were further interested whether PnG was not only able to release final 
products, but also premature products (i.e. , di-, tri- and tetraketide) in pentaketide assays. 
The growing polyketide is intermolecular translocated between PnAV4 and the first module 
of PnB, and also between the second module of PnB and PnC. In case of inefficient 
module interaction and/or translocation downstream, the polyketide chain will be exposed 
on the ACP and thus become a potential substrate for PnG. Consequently, an 
accumulation of diketide and tetraketide in the pentaketide system should be observed. 
Indeed, PnG dependent accumulation of di- and particularly tetraketide can be observed 
while no accumulation of triketide (intramolecular transfer) can be detected (Figure S12). 
This supports that PnG is able to release ACP tethered polyketides during translocation 
in an in vitro setting.  
 
Final discussion 
We biochemically characterized the type II thioesterase PnG and studied the effects of 
this enzyme on its cognate phoslactomycin modular type I PKS in vitro. PnG shows a 
strongly pronounced preference for decarboxylated acyl-residues bound to ACPs 
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compared to their carboxylated counterparts with up to 1500-fold increased specificity 
constant (kcat/KM). In addition, this enzyme prefers smaller, carboxylated substrates like 
malonyl-ACP over ethylmalonyl-ACP (50-fold higher kcat/KM). The data points towards that 
PnG removes aberrant ACP-tethered acyl-residues. 
Using the recently established in vitro Pn PKS system 30, we show that PnG leads 
to a higher polyketide production in the presence of the native but also non-native 
substrates. Addition of PnG to extender unit competition assays allows increases of up to 
14-fold higher product amounts. Our experiments demonstrate that the phoslactomycin 
assembly line is partially blocked by mis-loading during expression. This highlights the 
importance of editing TEIIs, as 4’phosphopantetheinyl transferases generally have a 
broad substrate tolerance and are able to transfer acylated phosphopantetheine arms to 
ACP 30, 33-35. Additionally, the assembly line stalls during biosynthesis, most likely due to 
a slow, unwanted decarboxylation of ACP-tethered (alkyl)malonyl residues. This 
decarboxylation activity has been conferred to the ketosynthase domains, leaving an 
ACP-tethered alkyl-residue that is unreactive for the subsequent condensation step 36-38. 
Notably, PnG does not only show hydrolysis activity towards short acyl-chains but 
also towards polyketides, as indicated by both the release of intermediates and in 
particular, the efficient penta- and hexaketide release of the system lacking a terminal 
thioesterase. This is simultaneously accompanied by the increase of product formation 
due to the editing role of PnG. In our in vitro system, PnG (and potentially other TEII) can 
therefore be used to replace the terminal TE, which might circumvent artifacts caused by 
their specificities, as seen for the hexaketide production. 
In substrate competition assays PnG shapes the product spectrum towards the 
native product. This effect becomes especially visible with increasing PnG 
concentrations, as the probability of removing modifications that are bound to the ACPs 
with decreased processing-efficiency increases. In summary, the low specificity towards 
decarboxylated substrates, ACPs and the shaping of the product profile support the low 
specificity model of TEIIs for PnG. The activity of PnG, given the fine balancing of its 
optimal concentration, overall increases product formation, even for non-native products, 
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Figure S1: SDS-Page analysis of PnG and PnG S93G. Insoluble fraction (1), lysate (2), Ni-NTA agarose 







Figure S2: Kinetic measurements of PnG hydrolytic activity towards ACP bound acyl-residues fitted to 
Michaelis Menten plot (GraphPad Prism 8.0.0) A) malonyl-ACPLD, B) acetyl-ACPLD, C) ethylmalonyl-ACPLD 
D) butyl-ACPLD, E) malonyl-ACP2, F) acetyl-ACP2, G) methylmalonyl-ACP2, H) propionyl-ACP2, 





Figure S3: Phoslactomycin (Pn) PKS. ACP=acyl carrier protein; AT=acyltransferase; DH=dehydratase; 
KR=ketoreductase; TE=thioesterase; 1=cyclohexanecarboxyl-CoA; 2=malonyl-CoA; 
3=(2S)-ethylmalonyl-CoA; 7=phoslactomycin polyketide backbone, 8=bioactive phoslactomycin 
derivatives; R=isobutyloxy; isovaleryloxy; 4-methylcaleryloxy; cyclohexylcarbonyloxy; 





Figure S4: Effect of increasing PnG concentration on polyketide production after 2 h and overnight. 
All sample series were normalized to the control sample without PnG. Concentrations of PnG, indicated on 
the x-axis ranged between 0.1 and 2 molar equivalents of ACPs present in the assay. In B, C and D the 
heat map indicates the initial product distribution, set relative to the natural product 5b. Residues indicated 
are: a=methyl-, b=ethyl-, c=butyl-, d=3-methlbutyl-, e=hexyl-residues. (A) Tetraketide production is 
increased up to five-fold. No effect of acetyl-CoA addition can be observed. (B) Pentaketide production in 
reaction mixtures containing malonyl-CoA and one α-substituted malonyl-CoA derivative as extender units. 
Increase in product formation can be seen for all pentaketide derivatives 5a-e. The strong increase of 5a 


























































































































































can be explained by the very little initial amounts close to the detection limit. The overall lower fold-changes 
in the overnight samples could be explained by the consecutive biosynthesis of pentaketides in the samples 
not containing PnG, while samples containing PnG ran out of resources. (C) Pentaketide production run 
under competitive reaction conditions, containing malonyl-CoA and all five α-substituted malonyl-CoA 
extender units. Initial product amount of 5b is highest, as well as the fold-change when PnG is added. (D) 
Pentaketide production with pre-treated Pn PKS enzymes. Treatment with PnG ensures removal of all 
potentially aberrant acyl-residues. PnG is removed by size exclusion chromatography from the Pn PKS 





Figure S5: PnG catalytic knockout control PnG S93G. The active site serine is mutated to a glycine, 
rendering it unable to covalently bind the substrate. This control was performed to assure that all effects, 
observed in the assays are due to PnG and not caused by protein contaminations. Shown here is the 
relative product amount of competitive pentaketide assays containing PnG S93G compared with assays 
containing no PnG. Samples containing PnG S93G, taken after 2 h and o.n., contain the same product 
amounts as samples without the type II thioesterase PnG. Residues indicated are: a=methyl-, b=ethyl-, 
c=butyl-, d=3-methlbutyl-, e=hexyl-residues.  























Figure S6: Tandem mass spectrometric analysis of native and non-native pentaketides 
Putative structures for the different polyketides were generated using knowledge on the biosynthetic logic 
of the phoslactomycin PKS system. The fragment masses were obtained by inspecting the data files using 
Xcalibur Qual Browser software. The experimental fragments were used to verify the proposed structure of 
the molecules by drawing fragment structures to explain the observed fragment mass. The structures of 
the fragments were drawn using ChemDoodle software. All precursor ion and fragment ion masses differed 
by less than 5 ppm compared to the theoretical mass. In addition, in-silico fragmentation was performed 
using MetFrag online. However, the top scoring candidates had molecular formulas that are unnatural (eg. 
Contains Boron or Fluorine, or Halogen) and are not expected to be formed by the Pn PKS in vitro. A) 
Fragmentation pattern of 5a (methylmalonyl-CoA incorporation), B) Fragmentation pattern of 5b (native 
product, ethylmalonyl-CoA incorporation, C) Fragmentation pattern of 5c (butylmalonyl-CoA incorporation), 







Figure S7: Diketide SNAC thioester impacts PnGs activity. The x-axis in A and B indicates the 
concentration of PnG, equimolar towards the ACPs present, samples taken after 2 h. (A) Pn polyketide 
production can be initiated by PnAV4 (panel 1). Alternatively, PnAV4 can be bypassed when the respective 
diketide SNAC analog, serving as a substrate for PnB is added (panel 2). When initiated with PnAV4 
tetraketide production increased five-fold, surprisingly when bypassing PnAV4 and supplying the SNAC 
ester, no effect of PnG was detected. When producing the pentaketide 5b, a 14-fold increase in production 
upon PnG addition is observed, however when bypassing PnAV4 5b production increases maximal seven-
fold. Either PnG has a differential effect on PnAV4, PnB and PnC-TEDEBS or the SNAC-ester has an 
inhibition-like effect on PnG. (B) To test if the diketide-SNAC analog is responsible for the decrease of 
PnGs effect on polyketide production, we ran 5b production assays with PnAV4, PnB, PnC-TEDEBS (a), PnB, 
PnC-TEDEBS (b) and PnAV4, PnB, PnC-TEDEBS plus the diketide-SNAC ester (c). A six-fold increase was 
observed in a, however in b and c an increase of only approximately four-fold was measured. This leads to 
the assumption that the diketide SNAC analog impacts PnG activity. SNAC thioesters also serve as 
substrates for thioesterases, however with a slower turnover. PnG most likely binds the SNAC ester as 









Figure S8: PnG does not hydrolyze CoA-thioesters. Incubation of PnG with the CoA-thioester substrates 
present in the polyketide production assays. Samples from assays containing PnG and without PnG as 
negative control were taken after 0 h, 2 h and 4 h. Neither buildup of free CoA-SH, nor depletion of the acyl-








CoA with PnG, D) and without PnG. E) Methylmalonyl-CoA with PnG, F) and without PnG. G) Ethylmalonyl-
CoA with PnG, H) and without PnG. I) Butylmalonyl-CoA with PnG, J) and without PnG. K) 






Figure S9: Effect of PnG on the product profile in competitive pentaketide assays. All samples are 
normalized to the 5b ion count in the same sample. When comparing the products in competitive assays it 
shows that all alternative products relatively decrease upon addition of PnG (while the absolute amount of 
product increases for all – compare to Figure S4). This shaping in product profile towards the natural product 
5b could be caused a longer exposure of non-native acyl-residues due to slower processing. The longer 
exposure results in a higher probability of PnG to hydrolyze the residue, which increases with higher PnG 






Figure S10: Effect of PnG on the pentaketide production and release without terminal thioesterase. 
Pn PKS assembly line is missing the terminal thioesterase (PnAV4-PnB-PnC). Residues indicated are: 
a=methyl-, b=ethyl-, c=butyl-, d=3-methlbutyl-, e=hexyl-residues. Concentrations of PnG ranged between 
0.1 and 2 molar equivalents of ACPs present in the assay. Pentaketide production was run under 
competitive reaction conditions, all mixtures contained malonyl-CoA and all α-substituted extender units. 
A) Pentaketide production after 2 h and overnight (o.n.) incubation of the assay. All sample series were 
normalized to the control sample without PnG. The heat map displays the product distribution of non-native 
pentaketides (5a, 5c-d) compared to the native pentaketide 5b in absence of PnG. A strong increase of 
product formation after 2 h can be observed for all pentaketides, particularly 5b-5c (200- to 100-fold 
increase respectively). The effect of PnG on product formation becomes less prominent in the overnight 
samples. This is most likely due to slow but consistent production of pentaketides in the assays not 



























































and with a terminal thioesterase (PnAV4 + PnB + PnC-TEDEBS) to identify if PnG can functionally reconstitute 
the terminal TE, samples after 2 h and overnight (o.n.). In absence of PnG product formation reaches only 
5% of the level when a terminal TE is present. This supports the importance of the fusion of TEDEBS to PnC 
for pentaketide release. Upon addition of PnG final product amount in ion counts reaches up to approx. 
90% (5b), 80% (5c) and 55% (5d) of that, if TEDEBS was present. PnG is able to hydrolyze the pentaketide 
product bound to PnC. 
 
Figure S11: Release of hexaketides by PnG. The x-axis shows the concentration of PnG, equimolar to 
ACPs present in the assay. On the left side, PnG has been added to assays terminating with TEDEBS (PnAV4, 
PnB, PnC, PnD-TEDEBS), on the right side without TEDEBS (PnAV4, PnB, PnC, PnD). A five-fold increase in 
product formation can be observed upon addition of PnG to assays terminating with TEDEBS, while a 20-fold 
increase can be observed in absence of TEDEBS. In the control samples without PnG, assays terminating 
without TEDEBS contain two-fold higher product amounts then when a terminal TE is present. This shows a 
negative influence of the terminal TE from DEBS on Pn hexaketide production.  
 
 




Figure S12: Release of intermediates from Pn PKS pentaketide system. Initiation with PnAV4 and 
termination with PnC-TEDEBS. Shown are the peak areas of samples with increasing PnG concentration 
relative to the control without PnG. Concentrations of PnG ranged between 0.1 and 2 molar equivalents of 
ACPs present in the assay. CHC=cyclohexanecarboxylic acid (C7H12O2; calculated: m/z [H+]: 129.091; m/z 
[Na+]: 151.073; found: m/z [Na+]: 151.0758; retention time 8.5 min), diketide (C9H14O2; calculated: m/z [H+]: 
155.1067; m/z [Na+]: 177.0886; found: m/z [Na+]: 177.0926; retention time 8.5 min), triketide (C11H16O2; 
calculated: m/z [H+]: 181.1223; m/z [Na+]: 203.1043; found: m/z [Na+]: 203.1088; retention time 9 min), 
tetraketide (C13H20O3; calculated: m/z [H+]: 225.1485 ; m/z [Na+]: 247.1305; dehydrated C13H18O2; m/z [H+]: 
207.138; m/z [Na+]: 229.1199; found m/z [H+] 207.1397; retention time 7 min). No difference can be 
observed between the 2 h and overnight (o.n.) samples. Release of triketide cannot be observed. The tri- 
and tetraketide are produced by the bi-modular protein PnB. The triketide is internally translocated to the 


































































CHC diketide triketide tetraketide
2 h 2 h 2 h 2 ho.n. o.n. o.n. o.n.
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Table S1: List of polyketide masses (m/z) from the in vitro production assays. Both, m/z calculated 
and detected are given together with the retention time. 4 corresponds to the tetraketide, 5 to the 












4 7.1 207.1380 207.1403 0.0023 229.1199 -  
5a 8.1 263.1642 263.1648 0.0006 285.1461 285.1316 0.0145 
 8.1 245.1536 245.1546 0.0010 267.1355 -  
5b 8.5 277.1798 277.1818 0.0020 299.1618 299.1635 0.0017 
 8.5 259.1693 259.1710 0.0017 281.1512 -  
5c 9.2 305.2111 305.2130 0.0019 327.1931 327.1948 0.0017 
 9.2 287.2006 287.2025 0.0019 309.1825 -  
5d 9.5 319.2268 319.2287 0.0019 341.2087 341.2105 0.0018 
 9.5 301.2162 301.2180 0.0018 323.1982 -  
5e 9.8 333.2424 333.2439 0.0015 355.2244 355.2313 0.0069 




Synthesis of substrates. Acyl-CoA synthesis was done like previously described. CHC-
CoA was synthesized by chemical CDI coupling of the free acid, analogous as previously 
explained 3. The diketide-SNAC was synthesized as previously reported 4 
 
Expression plasmid cloning. Preparation of the constructs for expression of PnAV4, 
PnB, PnC and PnC-TEDEBS was reported before 4. PnG coding sequence (optimized for 

















The PnG coding sequence was inserted between the NdeI and HindIII multiple cloning 
sites of pET28b(+). The ordered sequence contained 5’- and 3’- overhangs of 8bp length 
to enable restriction by NdeI and HindII. pET28b(+) was digested with the same 
overhangs and the PnG and linearized pet28b(+) was purified from 0.8% agarose gel and 
ligated by T4 ligase mediated reaction. Single colonies were picked, grown, the plasmid 
isolated and sequenced.  
 
Protein production and Nickel NTA-purification. Expression constructs encoding for 
the Pn PKS were transformed in E. coli BAP1 competent cells, all other proteins used in 
this study, including standalone ACP domains, were transformed in E. coli BL21 (DE3) 
competent cells and supplemented with the respective antibiotics. For PnG 1 L Terrific 
Broth medium was inoculated from plate and grown at 37 °C until OD600 reached 1.8. The 
culture was placed shaking at 23 °C and expression was induced with 100 µM isopropyl-
β-D-thiogalactopyranoside. After 4 h of incubation, the culture was harvested and used 
for protein purification or stored at -20 °C. For all other expressions a 10 mL overnight 
culture was grown and used to inoculate 1 L Terrific Broth medium. The cultures were 
grown at 37 °C until an OD600 of 1 was reached, then placed shaking at 18 °C (Pn PKS 
proteins) or 20 °C overnight. The cultures were harvested and used for protein purification 
or stored at -20 °C. Cell pellets were resuspended in Buffer A (500 mM NaCl, 50 mM 
NaH2PO4, 10% v/v glycerol, pH 7.5) and lysed by sonication, centrifuged at 42.000 g, 
4 °C for 45 min and the supernatant was mixed with 3.5 mL Protino® Ni-NTA Agarose 
purchased from Macherey Nagel and incubated for 2 h on ice with slow shaking. The 
beads solution was transferred into Protino® Columns 14 mL, washed with 50 mL Buffer 
A. Following the beads were washed with 20 mL washing buffer (25 mM Imidazole, 
500 mM NaCl, 50 mM NaH2PO4, 10% v/v glycerol, pH 7.5). Proteins were eluted with 
8 mL Buffer B (500 mM Imidazole, 500 mM NaCl, 50 mM NaH2PO4, 10% v/v glycerol, 
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pH 7.5). PnG and all standalone ACP proteins were further purified by size exclusion 
using HiLoad 16/600 Superdex 200 pg column (300 mM NaCl, 25 mM NaH2PO4, pH 7.5). 
Pn PKS proteins were subjected to anion exchange. Protein concentration was 
determined by UV-vis measurements at 280 nm, in the case of ACPs concentration was 
determined by Bradford assay. 
 
Anion exchange. The eluate from the Nickel beads purification was diluted to 120 mL 
with Anion A (50 mM NaH2PO4, pH 7.5) and loaded onto a 5 mL HiTrap Q HP anion 
exchange 5 mL chromatography column, purchased from GE Healthcare Life Sciences, 
with a flow of 3 mL/min. A gradient to 100% Anion B (50 mM NaH2PO4, 500 mM NaCl 
pH 7.5) with a flow of 4 mL/min in 30 min was run and protein containing fractions were 
collected and concentrated using Amicon® Ultra Centrifugal Filters, purchased from 
Merck Millipore. Proteins were used immediately for assays or stored with 30% v/v 
glycerol in -80 °C after shock freezing in liquid nitrogen. 
 
Pn PKS and PnG in vitro assays. The production of phoslactomycin polyketide 
derivatives was initiated using PnAV4 and cyclohexanecarboxyl-CoA. The assay was run 
at a volume of 50 µL and contained the 5 µM Pn PKS proteins, 3.5 µM Npt, 1 mM 
cyclohexanecarboxyl-CoA, 1 mM malonyl-CoA and 0.5 mM α-substituted malonyl-CoA 
derivatives (in single extender unit assays all extender units were used at 1 mM 
concentration), 5 mM NADPH, 0.1 mM CoA and 5 mM MgCl2. The reaction was buffered 
with 100 mM NaH2PO4. PnG concentrations used in the assay varied and were adjusted 
to the ACPs present in the assay solution. PnG relative concentrations were 0.1, 0.25, 
0.5, 1 and 2, whereas a PnG concentration of 1 equals the molar concentration of ACPs 
in the whole assembly line and 0.1 a tenth of the ACPs present. When bypassing PnAV4, 
(2Z)-cyclohexanepropenyl-SNAC4 was used as the diketide substrate analog. 
Immediately after mixing the reaction, 10 µL were added to 10 µL Methanol, as the 
negative control. The assay was run at 25°C and samples were taken after 2 h and 
overnight and quenched 1:1 with methanol.  
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Polyketide production assay with pretreated Pn PKS enzymes. The phoslactomycin 
production assays to assure the effect on production originates from continuous PnG 
activity was done as followed. It had to be assured, that the Pn PKS proteins are free of 
any mis-loaded acyl-residues bound to the ACPs. For this, PnAV4, PnB and PnC-TEDEBS 
were expressed as previously described. After the Ni-NTA purification the proteins 
(including PnG) were desalted using PD-10 column and concentrated to a volume of 
approximately 1 mL. Each Pn PKS enzyme was treated separately with 5 µM Npt, 1 mM 
CoA, 5 µM PnG for 45 min in 10 mM MgCl2, 100 mM NaH2PO4 at 28°C (assures complete 
activation of the ACPs to form holo-ACPs and complete removal of eventual acyl-residues 
bound to the ACPs). After this treatment the Pn PKS enzymes were cleared of PnG and 
CoA by size exclusion chromatography on a HiLoad 16/600 Superdex 200 pg column 
(300 mM NaCl, 25 mM NaH2PO4, pH 7.5). The assay was run at a volume of 50 µL and 
contained 5 µM Pn PKS proteins, 1 mM cyclohexanecarboxyl-CoA, 1 mM malonyl-CoA 
and 0.5 mM of each α-substituted malonyl-CoA derivatives, 5 mM NADPH and 100 mM 
NaH2PO4. PnG concentrations used in the assay varied and were adjusted to the number 
of ACPs present in the assay solution. Used PnG relative concentrations were 0.1, 0.25, 
0.5, 1 and 2, whereas a PnG concentration of 1 equals the molar concentration of ACPs 
in the whole assembly line. Immediately after mixing the reaction, 10 µL were added to 
10 µL Methanol, as the negative control. The assay was run at 25°C and samples were 
taken after 2 h and overnight and quenched 1:1 with methanol. 
 
High resolution mass spectrometric analysis of the polyketide production assay. 
All samples were measured immediately or stored at -80°C. UPLC-high resolution MS 
analysis was carried out using an Agilent 6550 iFunnel QTOF LC-MS system equipped 
with an electrospray ionization source set to positive ionization mode. The analyte was 
separated on a RP-18 column (50 mm x 2.1 mm, particle size 1.7 µm, Kinetex EVO C18, 
Phenomenex) using a mobile phase system comprised 0.1% formic acid in water (Solvent 
A) and acetonitrile (Solvent B). Chromatographic separation was carried out using the 
following gradient condition at a flow rate of 250 µL min-1: 0 min 5% B; 1 min 5% B, 6 min 
95% B; 6.5 min 95% B; 7 min 5% B. The column oven was set to 40°C and auto sampler 
was maintained at 8 °C. Standard injection volume was 10 µL. Capillary voltage was set 
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at 3.5 kV and nitrogen gas was used as nebulizing (20 psig), drying (13 L min-1, 225 °C) 
and sheath gas (12 L min-1, 40°C). MS data were acquired with a scan range of 50-1200 
m/z. LC-MS data were analyzed using MassHunter Qualitative Analysis software 
(Agilent). 
 
Tandem mass spectrometry analysis of pentaketides. Determination of polyketides 
was performed using a HRES-LC-MS. The chromatographic separation was performed 
on an Thermo Scientific Vanquish HPLC System using a Kinetex Evo C18 column (50 x 
.12mm, 100 A, 1.7 µm, Phenomenex) equipped with a 20 x 2.1 mm guard column of 
similar specificity at a constant eluent flow rate of 0.25 ml/min and a column temperature 
of 40 °C with eluent A being 0.1% formic acid in water and eluent B being 0.1% formic 
acid in acetonitrile (Honeywell). The injection volume was 2 µl. The elution profile 
consisted of the following steps and linear gradients: 0 – 2 min constant at 0% B; 2 – 11 
min from 0 to 100% B; 11 – 12 min constant at 100% B; 12 – 13 min from 100 to 0% B; 
13 – 14 min constant at 0% B. A Thermo Scientific ID-X Orbitrap mass spectrometer was 
used in positive mode with an electrospray ionization source and the following conditions: 
ESI spray voltage 5000 V, sheath gas at 45 arbitrary units, auxiliary gas at 9 arbitrary 
units, sweep gas at 7 arbitrary units, ion transfer tube temperature at 300°C and vaporizer 
temperature at 325 °C. Scheduled targeted collision induced dissociation was performed 
on the five suspect molecules, applying a precursor ion scan at a mass range between 
200 and 400 m/z with a mass resolution of 120000 using the orbitrap mass analyzer after 
quadrupole pre-isolation. Data dependent detection of MS2 spectra was performed at a 
normalized collision energy of 30% and an activation Time of 10 ms with an automatic 
definition of the scan range and a mass resolution (MS2) of 120000 using the orbitrap 
mass analyzer. 
 
Kinetic analysis of PnG. ACP loading reactions contained 2 mM ACP, 10 µM Npt, 5 mM 
MgCl2 and 2.4 mM acyl-CoA (exception butyl-CoA where 1.5 mM ACP and 1.6 mM 
butyl-CoA were used). After incubation of the loading reaction for 2 h at 28 °C the reaction 
was stored on ice. For the kinetic characterization of PnG mixtures with individual 
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concentrations of acyl-ACP (end concentrations between 1.8 mM and 5 µM) were treated 
with PnG (end concentration 20 nm in case of decarboxylated alkyl-ACPs and 500 nm in 
case of carboxylated acyl-ACPs) for individual durations between 1 and 20 minutes in a 
total volume of 10 µL. Subsequently the reactions were quenched with 10 µL of 20% (v/v) 
formic acid. The quenched reaction solutions were diluted with water to a final ACP 
concentration of 10 µM. 2 µL of the buffered protein solutions were desalted online using 
a Waters ACQUITY H-Class HPLC-system equipped with a MassPrep column (Waters). 
Desalted proteins were eluted into the ESI source of a Synapt G2Si mass spectrometer 
(Waters) by the following gradient of buffer A (water with 0.05% formic acid) and buffer B 
(acetonitrile with 0.045% formic acid) at a column temperature of 60 °C and a flow rate of 
0.1 mL/min: Isocratic elution with 5% A for two minutes, followed by a linear gradient to 
95% B within 8 minutes and holding 95% B for additional 4 minutes. Positive ions within 
the mass range of 500-5000 m/z were detected. Glu-Fibrinopeptide B was measured 
every 45 s for automatic mass drift correction. Averaged spectra were deconvoluted after 
baseline subtraction and eventually smoothing using MassLynx instrument software with 
MaxEnt1 extension. 
 
PnG hydrolysis of CoA-thioesters. To assure that PnG does not hydrolyze polyketide 
substrates an Ultra High Performance Liquid Chromatography supported assay was 
done. For this, 5 µM PnG was incubated with 1 mM malonyl-, methylmalonyl-, 
ethylmalonyl-, butylmalonyl-, 3-methylbutylmalonyl-, hexylmalonyl- or 
cyclohexanecarboxyl-CoA in 50 mM NaH2PO4, pH 7.5 at 25°C. The control to test for 
background hydrolysis of the CoA esters did not contain PnG. Samples were taken at 
0 min, 60 min and 240 min and quenched with formic acid (final in sample 10% v/v). The 
samples containing malonyl-, methylmalonyl- and ethylmalonyl-CoA were separated on 
Eurospher II 100-2 C18 column (100 x 2 mm, Knauer). Separation of these CoA-
thioesters in the reaction samples was done with a gradient of 1.5 – 10% (v/v) acetonitrile 
in 10 mM potassium phosphate buffer (pH 6.8) over 6.5 min at a flow rate of 0.2 mL min-1 
at 50 °C. The samples containing cyclohexanecarboxyl-, butylmalonyl-, 
3-methylbutylmalonyl- and hexylmalonyl-CoA were separated on Luna 100-2 C18 column 
(150 x 4.6 mm, Phenomenex). Separation of these CoA-thioesters in the reaction 
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samples was done with a gradient of 2 – 18% (v/v) acetonitrile in 25 mM 
ammoniumformiate buffer (pH 8.1) over 9 min at a flow rate of 0.25 mL min-1 at 30 °C. To 
detect the CoA-thioesters via UV absorbance at 260 nm an InfinityLab Max-Light 
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Polyketide synthases (PKS) are unique multifunctional enzymes with a modular 
organization. Each module incorporates a specific substrate and collaborates with 
downstream modules to assemble complex polyketides. Inspired by the modularity of 
PKS and the prospects of mixing and matching modules for the generation of de novo 
biosynthetic pathways, they have been targeted in synthetic biology approaches 1, 2. 
Despite their promising potential for applying rational engineering, which would result in 
the production of new-to-nature chemicals, there has been a slowly progressing success. 
This is mainly due to an incomplete knowledge about their structure, the interaction 
between modules and the growing polyketide, in addition to a neglected in-depth 
biochemical characterization of whole polyketide synthases, modules, single domains 
and accessory enzymes. The difficulties in gaining full understanding of PKS, result in 
part from the little diversity of in vitro model systems. The investigation of multiple as well 
as more diverse model systems could aid in the better understanding of this class of 
enzymes. The labor-intensive synthesis of PKS substrates also impedes such in depth 
investigations. The characterization of wild type PKS, as well as engineered PKS is 
pivotal to the identification of bottlenecks caused by gatekeeping behaviors of single 
domains. Furthermore, particularly in the in vivo context, other enzymes might affect 
polyketide biosynthesis. This factor is often disregarded, when transferring in vitro 
knowledge to in vivo systems and leads to unsuccessful implementation of engineered 
PKS that seemed to be promising.  
This work aims on tackling multiple of the here presented challenges. It 
demonstrates a resource efficient workflow for the chemo-enzymatic synthesis of a 
plethora of extender units. This enables in-depth biochemical characterization of PKS. 
The under-studied phoslactomycin (Pn) PKS was selected for in vitro reconstruction. It 
exhibits a unique substrate selectivity and complementing characteristics to preexisting 
model systems. Challenging the in vitro Pn PKS system with a versatile set of extender 
units led to the identification of a promiscuous module and the derivatization of Pn PKS 
derived polyketides. Furthermore, these assays allowed for the identification of 
bottlenecks in the naturally promiscuous wild type system, that cause an impeded 
incorporation of non-native extender units. Detailed kinetic analysis of the AT 
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(acyltransferase) domains in this system resulted in a deep understanding of extender 
unit selection. Finally, the TEII (type II thioesterase) an accessory enzyme from the 
phoslactomycin PKS, was identified to have a polyketide-production promoting effect, 
while simultaneously impacting polyketide diversification.  
 
Workflow for the production of versatile extender units  
The first challenge for thorough studies of PKS engineering, as well as for fundamental 
understanding of substrate selection and incorporation in polyketides, is the supply of 
extender units. An easily accessible and efficient supply path of diverse substrates with 
the correct stereochemistry is required. The common route for polyketide extender unit 
synthesis is ligation of malonic acid derivatives to CoA-SH by the ligase MatB 3. While 
this is highly efficient with malonate and methylmalonate, this route is limited by the 
narrow substrate specificity of MatB for dicarboxylic acids (e.g. malonate) with short to no 
α-substitutions. Engineering of MatB resulted in broadening of its substrate spectrum from 
malonate- and methylmalonate towards for instance butylmalonate 3, 4. After resolving this 
bottleneck, the ligation reaction remained to be limited by the availability of α-substituted 
malonic acid derivatives, as they need to be commercially accessible or laboriously 
synthesized by acylation of Meldrums acid 5, 6.  Finally, the reaction products of MatB are 
in the (2R) configuration, which is not accepted as substrate by PKSs. Using MatB 
synthesized extender units therefore additionally requires the supply of an epimerase that 
is capable of providing the (2S) configuration of the different extender units, which would 
allow polyketide biosynthesis.  
In chapter I of this work, six ECR (enoyl-CoA carboxylase/reductase) homologues 
including one previously reported promiscuous, engineered ECR were investigated for 
their ability to produce a set of alkyl-malonyl-CoA derivatives with varying chain length, 
branching pattern and aromatic substituents. The benefits of ECR catalyzed extender unit 
synthesis are i) the availability to use a multitude of α,β-unsaturated acids that can 
chemically be coupled to CoA, ii) the native involvement and importance of ECR-II 
homologues in extender unit biosynthesis, iii) the immediate production of (2S) configured 
PKS substrates and iv) their high native substrate promiscuity 7. With detailed kinetic 
analysis, CcrCPAG, an engineered ECR-I from Caulobacter crescentus 7, was identified as 
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the homologue best-suited for polyketide extender unit biosynthesis, as it showed a 
pronounced substrate promiscuity and resulted in the highest carboxylation yields. Usage 
of this ECR circumvents the limitations of α-substitutions given in the case of MatB. Yet, 
the reductive side reaction of ECRs led to the accumulation of saturated byproducts, 
particularly phenylpropionyl-CoA, reducing overall product yield. To ensure efficient use 
of all resources, a system for byproduct recycling was sought. The previously described 
acyl-CoA oxidase Acx4 from Arabidopsis thaliana 8, which introduces the α,β-olefin group 
required for the ECR catalyzed carboxylation, was employed for biocatalytic proofreading. 
By recycling the saturated ECR reaction byproducts, the yield for benzylmalonyl-CoA 
production could be increased from 19% to 73% thereby reducing costs of this approach 
through efficient usage of CoA-SH.  
Remarkably, introduction of the oxidase opened an additional path for extender 
unit biosynthesis, as Acx4 enabled the usage saturated alkyl-CoA thioesters as starting 
substrates. This allows additionally to employ α,β-unsaturated acids, for the exploitation 
of commercially available saturated carboxylic acids. After establishing a workflow for 
synthesis at preparative scale, these extender units were used in substrate competition 
assays with the DEBS in vitro system. Extender unit incorporation could be observed and 
previously reported AT mutations that enhance promiscuity were verified.  
The synthesis of alternative extender units is however often hindered by the 
efficiency of the chemical coupling of CoA-SH to carboxylic acids, or acids carrying further 
functional groups, which can result in double activation with CoA or intramolecular 
cyclization. Enzymatic coupling could help to resolve this bottleneck, as for instance a 
double activation with CoA is highly unlikely through enzyme activation. An enzyme class 
that might be suited for conducting the ligation reaction are the middle chain fatty acyl-
CoA ligases (FACL), which provide long chain acyl-CoA thioesters. These enzymes are 
naturally involved in the biosynthesis of some rare PKS extender units, where their activity 
is coupled to the ECR carboxylation reaction 9. An additional point to add extender unit 
diversity is halogenation. Halogenation of natural products can lead to an increase in 
bioactivity, making such substrates of high interest for incorporation studies 10, 11. The 
ECR from salinosporamide PKS, SalG, catalyzes the carboxylation of 4-chlorocrotonyl-
CoA, resulting in chloroethylmalonyl-CoA 12. The modularity of the in chapter I described 
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extender unit synthesis route allows for the combination of FACL ligase reaction to 
ECR-catalyzed carboxylation with, if required, previous Acx4-catalyzed oxidation. This 
can be further combined with FACL engineering towards a broader substrate tolerance. 
The incorporation of thus produced novel extender units may lead to immediate, site 
specific functionalization of polyketides resulting in the production of novel polyketides 
with potentially improved bioactivities. 
In summary, the here presented ECR guided chemo-enzymatic synthesis enables 
the production a range of alkyl-malonyl-CoA extender units with the appropriate 
stereochemistry for polyketide biosynthesis. Additionally, biocatalytic proofreading allows 
for their production in high yields, paving the way for polyketide diversification and 
functional investigation of substrate selectivity. 
 
Phoslactomycin PKS in vitro system 
Retaining a high catalytic activity and efficiency in engineered PKS systems is required 
for efficient production of non-native polyketides. To accomplish this, a comprehensive 
biochemical understanding of the enzymatic mechanisms, for instance substrate 
specificity of domains and whole modules is pivotal. Studies showed that malonyl-CoA 
transferring AT domains are highly specific. On the other hand, alkyl-malonyl-CoA 
transferring AT domains have been shown to exhibit a broad substrate tolerance 13-17. 
Most studies that focused on understanding and shifting substrate specificity, used 
naturally promiscuous AT domains as a starting point, which complicated the identification 
of specificity-conferring amino acid residues. The observation that multiple alkyl-malonyl-
CoA transferring AT domains were capable of transacylating non-native substrates leads 
to the assumption that this is a general property of alkyl-malonyl-CoA transacylating AT 
domains.  
Studying specificity, as well as promiscuity on the level of extender unit selection, 
requires a system, that ideally displays both behaviors. To tackle this problem, a new PKS 
model was sought, which exhibits both extender unit specificity and promiscuity. In the 
native context, Pn PKS incorporates the rare starter unit cyclohexanecarboxyl-CoA, five 
molecules of malonyl-CoA and two molecules of ethylmalonyl-CoA per full elongation 
cycle. It thus offers the possibility to study AT-substrate specificity for different extender 
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units, enabling insightful comparisons of domain reaction parameters in one closed 
system. Chapter II describes the reconstitution of the first six modules of Pn PKS in vitro 
with controlled product release at different sites, which resulted in the production of tetra-, 
penta- and hexaketides. Substrate incorporation assays showed that malonyl-CoA 
incorporating modules exclusively accept their native substrate, while the ethylmalonyl-
incorporating fourth extending module PnC, incorporates all tested α-substituted extender 
units (methyl-, ethyl-, butyl-, 3-methylbutyl-, hexyl- and benzyl-malonyl-CoA). This 
supports the general promiscuity of alkyl-malonyl-CoA transacylating AT domains. PnC 
had a preference for medium chain length and branched residues, while malonyl-CoA 
was efficiently excluded from incorporation. Other promiscuous AT domains showed 
discrimination against longer and particularly, branched alkyl-residues 15, 17-19, rendering 
PnC_AT a domain with a remarkable broad substrate spectrum. Among all PKS domains, 
ATs show the greatest potential for engineering. The newly gained knowledge about 
PnC_AT can be used for diversification of phoslactomycins by supplying alternative 
extender units during in vivo production. Furthermore, it is conceivable to use PnC_AT 
for domain exchanges with PKS that are carefully chosen according to known restrictions 
of the systems, resulting in the diversification of different polyketides 20. 
Pentaketide structures with the native and non-native alkyl-residues were 
proposed based on Pn PKS biosynthetic logic and TEDEBS preference for lactone 
formation 21. The proposed structures were supported by tandem mass spectrometric 
analysis. Noteworthy, pentaketides with C-2 substitutions longer than the two-carbon 
chain of an ethyl-residue, were not found in the reduced form, indicating that PnC_KR 
(ketoreductase) does not accept these non-native polyketides as a substrate. 
Subsequently, PnD can extend the native and non-native pentaketides to the respective 
hexaketides. It shows a preference for short residues at the C-2 position of the 
pentaketide, most likely conveyed by PnD_KS (ketosynthase). Either substrates with C-2 
substitutions longer than ethyl-residues, or non-reduced pentaketides are excluded by 
the KS domain, since these were detected in lower amounts than anticipated. Depending 
on which scenario, future engineering should target either the KS or the KR-domain. 
Limitations caused by KS gatekeeping have been explored in trans-AT PKS 22, 23 and 
identified as well as elucidated in other cis-AT PKS 17, 24, 25. One of the biggest challenges 
193 
 
in successful PKS engineering, will be the identification of mutations that affect 
gatekeeping behavior, while at the same time not affecting selectivity of domains and 
overall catalytic activity. Studies aiming to modify the structure of phoslactomycin derived 
polyketides will thus require a deeper examination of the bottlenecks reported in this study 
and the identification and implementation of promiscuity-promoting or substrate 
preference-shifting mutations.  
The AT domains from Pn PKS were analyzed in detail with a steady state kinetic 
assay established for this work. This assay couples CoA-SH release to NADH 
consumption by utilizing the succinyl-CoA synthetase complex SucC/SucD from 
Escherichia coli with the pyruvate kinase/lactic dehydrogenase complex. It relies 
exclusively on purified proteins and allows for a continuous photometric, as well as 
fluorometric monitoring of enzyme reactions with nanomolar AT concentrations, under 
multiple turnover conditions. The reaction parameters support the strict substrate 
specificity of the malonyl-CoA transferring AT domains, previously observed in the here 
presented polyketide production assays. These AT domains, from PnA, PnB and PnD, 
discriminate against non-native substrates, most likely by the accessibility of the active 
site, as substrates carrying α-substitutions may not fit into the binding pocket. In contrast, 
PnC_AT, which native substrate is ethylmalonyl-CoA, can hydrolyze and transacylate all 
tested extender units. Intriguingly, it transfers the malonyl-residue onto its cognate ACP, 
although no incorporation into the pentaketide could be observed. This indicates the need 
for a more elaborate mechanism of influencing substrate specificities, than simply spatial 
restrictions. In the first half reaction of transacylation, an acyl-O-AT intermediate is 
formed. Here, a broad substrate tolerance of PnC_AT was observed, as hydrolysis and 
thus covalent binding to the active site for all tested substrates could be detected. This 
supports the theory that substrate discrimination does not take place during the acyl-O-AT 
intermediate formation 26. In the second half reaction the acyl-residue is either 
hydrolytically released or transferred onto the ACP. The hydrolysis rate was virtually the 
same for all acyl-residues, implying that hydrolysis does not impact substrate selectivity. 
The transacylation reaction however, varied strongly depending on which acyl-residue is 
being transferred onto the ACP. For example, a hundred-fold higher transacylation rate 
was observed for the native substrate ethylmalonyl-CoA, over the non-native substrate 
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malonyl-CoA. The measured transacylation rates correlate with the incorporation patterns 
observed in substrate competition assays and show that specificity is controlled in the 
second half reaction by differential rates of transacylation.  
Together, the results presented here, highlight Pn PKS as a powerful model to 
study PKS enzymology. The in vitro reconstitution of Pn PKS led to the identification of 
substrate preferences of single domains towards extender units, as well as growing 
polyketide chains. Limitations caused by the KR and KS domains towards non-native 
polyketides could be identified. With the ability to synthesize and supply a wide range of 
extender units PnC_AT could be identified as a highly promiscuous AT domain with the 
potential use for phoslactomycin derivatization and construction of chimeric PKS. In depth 
kinetic characterization of PnC_AT domain allowed decrypting of the mechanism behind 
extender unit selection.  
 
Type II thioesterase PnG increases polyketide production efficiency 
The in vitro reconstitution of Pn PKS not only enabled the characterization of this enzyme 
complex in detail but also the effects of accessory enzymes on the megasynthase and on 
product formation. The study of PKS associated TEIIs is often restricted to assessing their 
substrate spectrum with thioester analogs or ACP tethered substrates. Until now, their in 
vitro study with cognate natural product biosynthetic enzymes, was limited to type II PKS 
and NRPS/PKS hybrids 27-30. Therefore, their impact on type I PKS in the well-defined in 
vitro settings remained unstudied. Chapter III aims on filling this knowledge gap, by the 
purification and biochemical characterization of PnG, the TEII from the Pn PKS and 
analyzing its effect on the reconstituted Pn PKS system. Investigation of PnG reaction 
parameters with a set of (alkyl)malonyl- and alkyl-residues presented on two different Pn 
ACPs revealed no preference for ACPs or alkyl-substituents. On the other hand, a higher 
specificity constant for malonyl- over ethylmalonyl-ACP and for the decarboxylated alkyl- 
over their cognate (alkyl)malonyl-ACP counterparts, could be measured. The reaction 
parameters suggest an editing role of PnG. The preferred substrates represent 
mis-loaded alkyl-residues and dead-end decarboxylation products. The activity of PnG 
integrates therefore well into the predominant function of TEIIs, which is editing by 
removal of ACP modifications that would otherwise stall assembly lines 31, 32. 
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Addition of PnG to Pn PKS assays led to an increase of tetra- and pentaketide 
production. To exclude that this effect stems solely from the clearing of alkyl-residues that 
originate from mis-loading by holo-ACP forming transferases, Pn PKS enzymes were 
cleared from eventual alkyl residues, prior to polyketide production assays. Subsequently 
it could be shown that the aberrant structures originate from mis-loading during protein 
expression in E. coli BAP1 which co-expresses a phosphopantetheinyl transferase. 
Importantly, they also arise during polyketide biosynthesis, supporting decarboxylation 
without subsequent condensation 27. It can be expected that PnG performs the same 
function in the in vivo context of the native producer Streptomyces platensis, where the 
promiscuous 4’phosphopantetheinyl transferases Npt, draws the prosthetic group from a 
pool of CoA-thioesters and free CoA-SH. In particular acetyl-CoA is present in high 
concentrations compared to free CoA-SH 28, resulting in a high probability of transferring 
alkylated prosthetic groups and hence producing inactive PKS enzymes. Thus, the 
activity of a TEII is required and crucial to assure the functioning of the cost intensive PKS 
enzymes in vivo. Concomitantly, supply of PnG to polyketide production assays resulted 
in a drastic increase of in vitro polyketide formation. 
Additionally, to increasing the amount of native and non-native polyketides, PnG 
caused a relative increase of the native product towards the non-native products in 
substrate competition assays, referred to as a product profile shaping. This effect is likely 
caused by an increased exposure time of non-native substrates on the surface of the 
ACP, as a result of missing interactions with downstream domains or loose interaction of 
the substrate with the ACP itself. Due to the increased exposure, PnG can access and 
remove the residues that block the assembly line with higher probability. An effect that 
becomes more pronounced with increasing PnG concentration. Engineering the 
incorporation of non-native substrates should focus on optimizing the interactions 
between substrate and domain, to increase PKS biosynthetic efficiency and to avoid 
removal of non-native substrates from the assembly line in vitro and in vivo. This is of 
particular importance as TEIIs are omnipresent in PKS and NRPS producing bacteria. 
PnG, and ultimately other editing TEIIs, could be used in similar assay setups like 
presented here, as an analytical tool to identify beneficial, interaction- and 
incorporation-promoting mutations. If a substrate is efficiently incorporated, addition of 
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PnG in increasing concentrations will result in a shaping of the product profile towards 
this (non-native) product. 
The high substrate tolerance of PnG, as shown by kinetic analysis and polyketide 
production assays supports the low specificity model for TEIIs 29, 30. To probe its 
promiscuity further, it was tested whether PnG can replace the terminal TEDEBS on PnC. 
Indeed, similar levels of pentaketides were reached, indicating that PnG can release 
these polyketides and substitute TEIs, while simultaneously increasing the polyketide 
production. PnG could potentially be used in other systems for chain release to 
circumvent restrictions caused by i) substrate specificities of the terminal TE, 
ii) unsuccessful cloning of terminal TEs or iii) insolubility of chimeric proteins. Most TEIIs 
are responsible for the hydrolysis of acyl-thioesters, therefore releasing carboxylic acids. 
In the case of the phoslactomycin-derived pentaketides, the retention times of PnG- and 
TEDEBS-released products are the same. Combined with the tandem mass spectrometric 
analysis, this indicates that these products contain the lactone ring formed most likely by 
spontaneous ring-closure after hydrolytic release.  
Similar to the pentaketide assays described before, additional tests aimed on the 
ability of PnG to replace PnD tethered TEDEBS. In the pentaketide assays, termination 
without TEDEBS resulted in only approximately 5% of the product formation. This supports 
the importance of TEDEBS for product release in that particular system and furthermore 
shows that substrates with C-2 substitutions with varying length can effectively be 
released by TEDEBS. In contrast to the strong decrease of pentaketide formation in the 
absence of TEDEBS, hexaketide production was two-fold increased. TEDEBS has been 
described as a promiscuous thioesterase. It is however optimized for the macrocyclization 
of substrates with a C-2 methyl and C-3 hydroxyl group, in the presence of an 
appropriately placed distal hydroxyl group 21, 31, 32. The efficient release of Pn PKS native 
and non-native pentaketides shows that the length of the C-2 substitution and (3R) 
configuration does not impair chain release. In the case of the phoslactomycin 
hexaketide, no C-2 substitution is present. A distal hydroxyl group for macrocyclization 
could however enable release by ring formation and therefore efficient hexaketide 
production. The impaired hexaketide production by PnD-TEDEBS could be a result of 
protein mis-folding or slower TEDEBS catalyzed product release due to the absence of a 
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C-2 substitution. It is further conceivable that TEDEBS competes for the substrate with the 
dehydratase from PnD, which leads to a decreased assembly line efficiency.  
Upon addition of PnG, production of the hexaketide was strongly increased, 
extending its polyketide releasing activity to the phoslactomycin derived hexaketide.  
Strikingly, addition of PnG had the strongest effect in the absence of TEDEBS, supporting 
its detrimental effect on the phoslactomycin hexaketide system. The observation that the 
terminal TE can be a bottleneck for polyketide production was also made in the pikromycin 
system 33. This highlights the importance of evaluating the activity and substrate spectrum 
of product-releasing terminal TEs in chimeric or engineered systems, as well as in 
mutasynthon approaches.  
The work presented here showcases the production-promoting effect of PnG for 
increasing modular type I PKS in vitro polyketide biosynthesis. It was shown that PnG 
can be used for the release of final products, without a pronounced specificity towards 
structural features, with the ability of replacing terminal thioesterases. To use PnG for 
product release, it is important to consider that many polyketides require cyclization to 
result in bioactive compounds. It cannot be expected that PnG released products regio-
selectively cyclize by spontaneous ring-formation. Thus, for ring-closure, a suited, 
terminal TE should be identified after the optimization of the PKS.  
Studies focusing on the in vivo production of phoslactomycins in the native and 
heterologous hosts should include PnG activity, particularly when applying PKS and 
metabolic engineering. Disregarding the function of TEIIs could yield in unsuccessful 
implementation of mutations or strongly reduced product titers. Mediated by PnGs great 
substrate tolerance, it is a valuable tool to test polyketide production of truncated, chimeric 
and engineered PKS. PnG does not show the strong substrate specificity-bias of a 
terminal thioesterase and simultaneously increases polyketide production.  
 
Future PKS research  
Engineering of type I PKS by abstracting and subsequent recombining modules and 
domains, has the potential to produce a multitude of chemicals of interest. This includes 
compounds that are not normally produced biologically and only with great synthetic 
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chemistry efforts. Despite the advances made in the field of PKS engineering, it remains 
to be a long road until the full potential of PKS synthetic biology can be unleashed. 
There is a strong need for the characterization of structural and conformational 
dynamics of PKS domains during biosynthesis. Particularly, regarding specific 
module-module interactions during the different steps of polyketide assembly and the 
interaction during polyketide-chain passage. A further focus will also be on the classical 
in vitro enzyme characterization, as presented in this dissertation, to broaden the 
collection on kinetic parameters and expand the enzyme toolbox. Carefully selected PKS, 
such as phoslactomycin PKS, can function as testbeds for detailed probing of the impact 
of mutations, domain swaps and mix-and-match approaches.  
Understanding of the structural, mechanistic, biochemical but also evolutionary 
background is fundamental for to PKS pathway refactoring. Research on large PKS 
systems revealed evolutionary relationships between the domains within one system. In 
more detail, processing domains are more closely related to the downstream, than to the 
upstream KS and tend to co-evolve. This has led to a revision of the canonical module 
boundaries, resulting in a redefinition thereof 34. Respecting these relationships and new 
boundaries for the construction of chimeric PKS has resulted in assembly lines retaining 
high catalytic efficiency 35. Bioinformatic tools are having an increasing importance for the 
analysis and selection of modules suited for joining in chimeric PKS pathways. The 
generation of reliable computational tools will be based on wet-lab experimental and 
structural data. The constant feeding of newly gained data will be vital for automatized 
PKS refactoring 36. If such automated PKS refactoring, that yields in the efficient 
production of desired compounds is achieved, further improvements can be gained by 
applying directed evolution combined with high throughput screening 20. 
For many compounds, generation of the carbon backbone is sufficient to yield in 
the final product. Production of, for instance specialty chemicals by the generation of 
chimeric PKS was shown, that can replace their petroleum based chemical synthesis 37. 
Extending this product palette could eventually lead to a reduction of anthropogenic 
emissions. For the generation of small molecule therapeutics, post-synthesis tailoring 
reactions are often necessary to create bioactivity. Identification, and modularization of 
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tailoring enzymes, will need to be addressed as a step following the production of fully 
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